ID   POL_HV1H2               Reviewed;        1435 AA.
AC   P04585; O09777; Q9WJC5;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   28-JAN-2026, entry version 266.
DE   RecName: Full=Gag-Pol polyprotein;
DE   AltName: Full=Pr160Gag-Pol;
DE   Contains:
DE     RecName: Full=Matrix protein p17;
DE              Short=MA;
DE   Contains:
DE     RecName: Full=Capsid protein p24;
DE              Short=CA;
DE   Contains:
DE     RecName: Full=Spacer peptide 1 {ECO:0000250|UniProtKB:P12497};
DE              Short=SP1;
DE     AltName: Full=p2;
DE   Contains:
DE     RecName: Full=Nucleocapsid protein p7;
DE              Short=NC;
DE   Contains:
DE     RecName: Full=Transframe peptide;
DE              Short=TF;
DE   Contains:
DE     RecName: Full=p6-pol;
DE              Short=p6*;
DE   Contains:
DE     RecName: Full=Protease;
DE              EC=3.4.23.16 {ECO:0000269|PubMed:32053707, ECO:0000269|PubMed:33542150};
DE     AltName: Full=PR;
DE     AltName: Full=Retropepsin;
DE   Contains:
DE     RecName: Full=Reverse transcriptase/ribonuclease H;
DE              EC=2.7.7.49 {ECO:0000250|UniProtKB:P03366};
DE              EC=2.7.7.7 {ECO:0000250|UniProtKB:P03366};
DE              EC=3.1.26.13 {ECO:0000250|UniProtKB:P03366};
DE     AltName: Full=Exoribonuclease H;
DE              EC=3.1.13.2;
DE     AltName: Full=p66 RT;
DE   Contains:
DE     RecName: Full=p51 RT;
DE   Contains:
DE     RecName: Full=p15;
DE   Contains:
DE     RecName: Full=Integrase;
DE              Short=IN;
DE              EC=2.7.7.- {ECO:0000305|PubMed:2349226};
DE              EC=3.1.-.- {ECO:0000305|PubMed:2349226};
GN   Name=gag-pol;
OS   Human immunodeficiency virus type 1 group M subtype B (isolate HXB2)
OS   (HIV-1).
OC   Viruses; Riboviria; Pararnavirae; Artverviricota; Revtraviricetes;
OC   Ortervirales; Retroviridae; Orthoretrovirinae; Lentivirus;
OC   Lentivirus humimdef1; Human immunodeficiency virus type 1.
OX   NCBI_TaxID=11706;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=3040055; DOI=10.1089/aid.1987.3.57;
RA   Ratner L., Fisher A., Jagodzinski L.L., Mitsuya H., Liou R.-S., Gallo R.C.,
RA   Wong-Staal F.;
RT   "Complete nucleotide sequences of functional clones of the AIDS virus.";
RL   AIDS Res. Hum. Retroviruses 3:57-69(1987).
RN   [2]
RP   SEQUENCE REVISION.
RA   Ogata N., Alter H.J., Miller R.H., Purcell R.H.;
RL   Submitted (JUN-1996) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RA   Chappey C.;
RL   Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   FUNCTION (INTEGRASE).
RX   PubMed=2349226; DOI=10.1073/pnas.87.11.4164;
RA   Farnet C.M., Haseltine W.A.;
RT   "Integration of human immunodeficiency virus type 1 DNA in vitro.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:4164-4168(1990).
RN   [5]
RP   DIMERIZATION (PROTEASE).
RX   PubMed=2162350; DOI=10.1016/s0021-9258(18)86974-5;
RA   Weber I.T.;
RT   "Comparison of the crystal structures and intersubunit interactions of
RT   human immunodeficiency and Rous sarcoma virus proteases.";
RL   J. Biol. Chem. 265:10492-10496(1990).
RN   [6]
RP   MUTAGENESIS OF HIS-1159; HIS-1163; GLN-1200; ASP-1211; SER-1228; ASP-1263;
RP   GLU-1299; ARG-1346 AND TRP-1382.
RX   PubMed=8420982; DOI=10.1016/s0021-9258(18)53969-7;
RA   Leavitt A.D., Shiue L., Varmus H.E.;
RT   "Site-directed mutagenesis of HIV-1 integrase demonstrates differential
RT   effects on integrase functions in vitro.";
RL   J. Biol. Chem. 268:2113-2119(1993).
RN   [7]
RP   MUTAGENESIS OF CYS-1187; CYS-1190; TRP-1208; ASP-1211; THR-1213; VAL-1222;
RP   SER-1228; THR-1262; ASP-1263; GLY-1270; ILE-1282; VAL-1298; GLU-1299;
RP   LYS-1306; ALA-1326 AND TRP-1382.
RC   STRAIN=Isolate WI3;
RX   PubMed=8035478; DOI=10.1128/jvi.68.8.4768-4775.1994;
RA   Cannon P.M., Wilson W., Byles E., Kingsman S.M., Kingsman A.J.;
RT   "Human immunodeficiency virus type 1 integrase: effect on viral replication
RT   of mutations at highly conserved residues.";
RL   J. Virol. 68:4768-4775(1994).
RN   [8]
RP   INTERACTION OF CAPSID WITH HUMAN PPIA/CYPA.
RX   PubMed=8513493; DOI=10.1016/0092-8674(93)90637-6;
RA   Luban J., Bossolt K.L., Franke E.K., Kalpana G.V., Goff S.P.;
RT   "Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A
RT   and B.";
RL   Cell 73:1067-1078(1993).
RN   [9]
RP   INTERACTION WITH HUMAN SMARCB1/INI1 (INTEGRASE).
RX   PubMed=7801128; DOI=10.1126/science.7801128;
RA   Kalpana G.V., Marmon S., Wang W., Crabtree G.R., Goff S.P.;
RT   "Binding and stimulation of HIV-1 integrase by a human homolog of yeast
RT   transcription factor SNF5.";
RL   Science 266:2002-2006(1994).
RN   [10]
RP   FUNCTION (PROTEASE).
RX   PubMed=7835426; DOI=10.1016/0014-5793(94)01370-g;
RA   Gaedigk-Nitschko K., Schoen A., Wachinger G., Erfle V., Kohleisen B.;
RT   "Cleavage of recombinant and cell derived human immunodeficiency virus 1
RT   (HIV-1) Nef protein by HIV-1 protease.";
RL   FEBS Lett. 357:275-278(1995).
RN   [11]
RP   FUNCTION (CAPSID PROTEIN P24).
RX   PubMed=8648689; DOI=10.1128/jvi.70.6.3551-3560.1996;
RA   Braaten D., Franke E.K., Luban J.;
RT   "Cyclophilin A is required for an early step in the life cycle of human
RT   immunodeficiency virus type 1 before the initiation of reverse
RT   transcription.";
RL   J. Virol. 70:3551-3560(1996).
RN   [12]
RP   MUTAGENESIS OF PRO-217; VAL-218; HIS-219; ALA-220; GLY-221; PRO-222;
RP   ILE-223; ALA-224 AND PRO-225, AND INTERACTION WITH HUMAN CYPA.
RX   PubMed=9223641; DOI=10.1006/jmbi.1997.1051;
RA   Yoo S., Myszka D.G., Yeh C., McMurray M., Hill C.P., Sundquist W.I.;
RT   "Molecular recognition in the HIV-1 capsid/cyclophilin A complex.";
RL   J. Mol. Biol. 269:780-795(1997).
RN   [13]
RP   MUTAGENESIS OF ASP-1211; ASP-1263 AND GLU-1299.
RX   PubMed=9573231; DOI=10.1128/jvi.72.6.4678-4685.1998;
RA   Gaur M., Leavitt A.D.;
RT   "Mutations in the human immunodeficiency virus type 1 integrase D,D(35)E
RT   motif do not eliminate provirus formation.";
RL   J. Virol. 72:4678-4685(1998).
RN   [14]
RP   MUTAGENESIS OF LYS-18; ARG-22 AND LYS-27.
RX   PubMed=10604476; DOI=10.1038/45272;
RA   Dupont S., Sharova N., DeHoratius C., Virbasius C.M., Zhu X.,
RA   Bukrinskaya A.G., Stevenson M., Green M.R.;
RT   "A novel nuclear export activity in HIV-1 matrix protein required for viral
RT   replication.";
RL   Nature 402:681-685(1999).
RN   [15]
RP   PROTEOLYTIC PROCESSING OF POLYPROTEIN.
RX   PubMed=10494040; DOI=10.1007/bf02253522;
RA   Chang Y.Y., Yu S.L., Syu W.J.;
RT   "Organization of HIV-1 pol is critical for Pol polyprotein processing.";
RL   J. Biomed. Sci. 6:333-341(1999).
RN   [16]
RP   FUNCTION (NUCLEOCAPSID PROTEIN P7).
RX   PubMed=9931246; DOI=10.1006/jmbi.1998.2460;
RA   Negroni M., Buc H.;
RT   "Recombination during reverse transcription: an evaluation of the role of
RT   the nucleocapsid protein.";
RL   J. Mol. Biol. 286:15-31(1999).
RN   [17]
RP   FUNCTION (NUCLEOCAPSID PROTEIN P7).
RX   PubMed=11044125; DOI=10.1128/jvi.74.22.10796-10800.2000;
RA   Cen S., Khorchid A., Gabor J., Rong L., Wainberg M.A., Kleiman L.;
RT   "Roles of Pr55(gag) and NCp7 in tRNA(3)(Lys) genomic placement and the
RT   initiation step of reverse transcription in human immunodeficiency virus
RT   type 1.";
RL   J. Virol. 74:10796-10800(2000).
RN   [18]
RP   GAG/GAG-POL RATIO.
RX   PubMed=11160682; DOI=10.1128/jvi.75.4.1834-1841.2001;
RA   Shehu-Xhilaga M., Crowe S.M., Mak J.;
RT   "Maintenance of the Gag/Gag-Pol ratio is important for human
RT   immunodeficiency virus type 1 RNA dimerization and viral infectivity.";
RL   J. Virol. 75:1834-1841(2001).
RN   [19]
RP   ACTIVE SITES (REVERSE TRANSCRIPTASE/RIBONUCLEASE H), AND MUTAGENESIS OF
RP   GLU-1065 AND ASP-1136.
RX   PubMed=12206668; DOI=10.1021/bi025871v;
RA   Cristofaro J.V., Rausch J.W., Le Grice S.F., DeStefano J.J.;
RT   "Mutations in the ribonuclease H active site of HIV-RT reveal a role for
RT   this site in stabilizing enzyme-primer-template binding.";
RL   Biochemistry 41:10968-10975(2002).
RN   [20]
RP   CIS/TRANS ISOMERIZATION (CAPSID PROTEIN P24).
RX   PubMed=11929983; DOI=10.1073/pnas.082100499;
RA   Bosco D.A., Eisenmesser E.Z., Pochapsky S., Sundquist W.I., Kern D.;
RT   "Catalysis of cis/trans isomerization in native HIV-1 capsid by human
RT   cyclophilin A.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:5247-5252(2002).
RN   [21]
RP   MUTAGENESIS OF HIS-400; CYS-405; HIS-421 AND CYS-426.
RX   PubMed=11932404; DOI=10.1128/jvi.76.9.4370-4378.2002;
RA   Guo J., Wu T., Kane B.F., Johnson D.G., Henderson L.E., Gorelick R.J.,
RA   Levin J.G.;
RT   "Subtle alterations of the native zinc finger structures have dramatic
RT   effects on the nucleic acid chaperone activity of human immunodeficiency
RT   virus type 1 nucleocapsid protein.";
RL   J. Virol. 76:4370-4378(2002).
RN   [22]
RP   PROTEOLYTIC PROCESSING (GAG-POL POLYPROTEIN).
RX   PubMed=12477841; DOI=10.1128/jvi.77.1.366-374.2003;
RA   Pettit S.C., Gulnik S., Everitt L., Kaplan A.H.;
RT   "The dimer interfaces of protease and extra-protease domains influence the
RT   activation of protease and the specificity of GagPol cleavage.";
RL   J. Virol. 77:366-374(2003).
RN   [23]
RP   QUATERNARY STRUCTURE (CAPSID PROTEIN P24).
RX   PubMed=12660176; DOI=10.1093/emboj/cdg143;
RA   Briggs J.A., Wilk T., Welker R., Krausslich H.G., Fuller S.D.;
RT   "Structural organization of authentic, mature HIV-1 virions and cores.";
RL   EMBO J. 22:1707-1715(2003).
RN   [24]
RP   FUNCTION (PROTEASE).
RX   PubMed=12505164; DOI=10.1016/s0014-5793(02)03764-x;
RA   Perales C., Carrasco L., Ventoso I.;
RT   "Cleavage of eIF4G by HIV-1 protease: effects on translation.";
RL   FEBS Lett. 533:89-94(2003).
RN   [25]
RP   CLEAVAGE (NUCLEOCAPSID PROTEIN P7).
RX   PubMed=15065874; DOI=10.1021/bi035625z;
RA   Tozser J., Shulenin S., Louis J.M., Copeland T.D., Oroszlan S.;
RT   "In vitro processing of HIV-1 nucleocapsid protein by the viral proteinase:
RT   effects of amino acid substitutions at the scissile bond in the proximal
RT   zinc finger sequence.";
RL   Biochemistry 43:4304-4312(2004).
RN   [26]
RP   SUBUNIT (REVERSE TRANSCRIPTASE/RIBONUCLEASE H), MUTAGENESIS OF
RP   488-PHE--GLN-490 AND LEU-821, AND PROTEOLYTIC CLEAVAGE (GAG-POL
RP   POLYPROTEIN).
RX   PubMed=15183348; DOI=10.1016/j.biocel.2004.02.020;
RA   Sluis-Cremer N., Arion D., Abram M.E., Parniak M.A.;
RT   "Proteolytic processing of an HIV-1 pol polyprotein precursor: insights
RT   into the mechanism of reverse transcriptase p66/p51 heterodimer
RT   formation.";
RL   Int. J. Biochem. Cell Biol. 36:1836-1847(2004).
RN   [27]
RP   FUNCTION (REVERSE TRANSCRIPTASE/RIBONUCLEASE H).
RX   PubMed=16221683; DOI=10.1074/jbc.m507839200;
RA   Purohit V., Balakrishnan M., Kim B., Bambara R.A.;
RT   "Evidence that HIV-1 reverse transcriptase employs the DNA 3' end directed
RT   primary/secondary RNase H cleavage mechanism during synthesis and strand
RT   transfer.";
RL   J. Biol. Chem. 280:40534-40543(2005).
RN   [28]
RP   MUTAGENESIS OF ASN-394.
RX   PubMed=16904152; DOI=10.1016/j.virol.2006.07.011;
RA   Thomas J.A., Shulenin S., Coren L.V., Bosche W.J., Gagliardi T.D.,
RA   Gorelick R.J., Oroszlan S.;
RT   "Characterization of human immunodeficiency virus type 1 (HIV-1) containing
RT   mutations in the nucleocapsid protein at a putative HIV-1 protease cleavage
RT   site.";
RL   Virology 354:261-270(2006).
RN   [29]
RP   FUNCTION (NUCLEOCAPSID PROTEIN P7).
RX   PubMed=17070549; DOI=10.1016/j.jmb.2006.09.081;
RA   Hagan N.A., Fabris D.;
RT   "Dissecting the protein-RNA and RNA-RNA interactions in the nucleocapsid-
RT   mediated dimerization and isomerization of HIV-1 stemloop 1.";
RL   J. Mol. Biol. 365:396-410(2007).
RN   [30]
RP   SUBUNIT (MATRIX PROTEIN P17).
RX   PubMed=17108052; DOI=10.1128/jvi.02122-06;
RA   Alfadhli A., Huseby D., Kapit E., Colman D., Barklis E.;
RT   "Human immunodeficiency virus type 1 matrix protein assembles on membranes
RT   as a hexamer.";
RL   J. Virol. 81:1472-1478(2007).
RN   [31]
RP   MUTAGENESIS OF SER-6; SER-9; SER-67 AND SER-72, AND POST-TRANSCRIPTIONAL
RP   MODIFICATION.
RX   PubMed=17656588; DOI=10.1110/ps.072987607;
RA   Saad J.S., Kim A., Ghanam R.H., Dalton A.K., Vogt V.M., Wu Z., Lu W.,
RA   Summers M.F.;
RT   "Mutations that mimic phosphorylation of the HIV-1 matrix protein do not
RT   perturb the myristyl switch.";
RL   Protein Sci. 16:1793-1797(2007).
RN   [32]
RP   SUBCELLULAR LOCATION (INTEGRASE).
RX   PubMed=18722123; DOI=10.1016/j.cub.2008.07.079;
RA   Christ F., Thys W., De Rijck J., Gijsbers R., Albanese A., Arosio D.,
RA   Emiliani S., Rain J.C., Benarous R., Cereseto A., Debyser Z.;
RT   "Transportin-SR2 imports HIV into the nucleus.";
RL   Curr. Biol. 18:1192-1202(2008).
RN   [33]
RP   FUNCTION (NUCLEOCAPSID PROTEIN P7).
RX   PubMed=18343475; DOI=10.1016/j.virol.2008.02.001;
RA   Kafaie J., Song R., Abrahamyan L., Mouland A.J., Laughrea M.;
RT   "Mapping of nucleocapsid residues important for HIV-1 genomic RNA
RT   dimerization and packaging.";
RL   Virology 375:592-610(2008).
RN   [34]
RP   SUBUNIT (CAPSID PROTEIN P24), AND FUNCTION (CAPSID PROTEIN P24).
RX   PubMed=19914170; DOI=10.1016/j.cell.2009.10.010;
RA   Byeon I.J., Meng X., Jung J., Zhao G., Yang R., Ahn J., Shi J., Concel J.,
RA   Aiken C., Zhang P., Gronenborn A.M.;
RT   "Structural convergence between Cryo-EM and NMR reveals intersubunit
RT   interactions critical for HIV-1 capsid function.";
RL   Cell 139:780-790(2009).
RN   [35]
RP   FUNCTION (PROTEASE).
RX   PubMed=19956697; DOI=10.1371/journal.pone.0007997;
RA   Castello A., Franco D., Moral-Lopez P., Berlanga J.J., Alvarez E.,
RA   Wimmer E., Carrasco L.;
RT   "HIV- 1 protease inhibits Cap- and poly(A)-dependent translation upon
RT   eIF4GI and PABP cleavage.";
RL   PLoS ONE 4:E7997-E7997(2009).
RN   [36]
RP   SUBUNIT (MATRIX PROTEIN P17).
RX   PubMed=19327811; DOI=10.1016/j.virol.2009.02.048;
RA   Alfadhli A., Barklis R.L., Barklis E.;
RT   "HIV-1 matrix organizes as a hexamer of trimers on membranes containing
RT   phosphatidylinositol-(4,5)-bisphosphate.";
RL   Virology 387:466-472(2009).
RN   [37]
RP   INTERACTION OF GAG POLYPROTEIN WITH PDZD8.
RX   PubMed=20573829; DOI=10.1128/jvi.00843-10;
RA   Henning M.S., Morham S.G., Goff S.P., Naghavi M.H.;
RT   "PDZD8 is a novel Gag-interacting factor that promotes retroviral
RT   infection.";
RL   J. Virol. 84:8990-8995(2010).
RN   [38]
RP   FUNCTION (INTEGRASE), AND INTERACTION OF INTEGRASE WITH HUMAN KPNA3.
RX   PubMed=20554775; DOI=10.1128/jvi.00508-10;
RA   Ao Z., Danappa Jayappa K., Wang B., Zheng Y., Kung S., Rassart E.,
RA   Depping R., Kohler M., Cohen E.A., Yao X.;
RT   "Importin alpha3 interacts with HIV-1 integrase and contributes to HIV-1
RT   nuclear import and replication.";
RL   J. Virol. 84:8650-8663(2010).
RN   [39]
RP   FUNCTION (NUCLEOCAPSID PROTEIN P7).
RX   PubMed=20828778; DOI=10.1016/j.virol.2010.08.013;
RA   Jalalirad M., Laughrea M.;
RT   "Formation of immature and mature genomic RNA dimers in wild-type and
RT   protease-inactive HIV-1: differential roles of the Gag polyprotein,
RT   nucleocapsid proteins NCp15, NCp9, NCp7, and the dimerization initiation
RT   site.";
RL   Virology 407:225-236(2010).
RN   [40]
RP   INTERACTION WITH MONKEY TRIM5.
RX   PubMed=23785198; DOI=10.1128/jvi.00713-13;
RA   Shi J., Friedman D.B., Aiken C.;
RT   "Retrovirus restriction by TRIM5 proteins requires recognition of only a
RT   small fraction of viral capsid subunits.";
RL   J. Virol. 87:9271-9278(2013).
RN   [41]
RP   DIMERIZATION (PROTEASE).
RX   PubMed=24132393; DOI=10.1007/s10930-013-9517-y;
RA   Naicker P., Seele P., Dirr H.W., Sayed Y.;
RT   "F99 is critical for dimerization and activation of South African HIV-1
RT   subtype C protease.";
RL   Protein J. 32:560-567(2013).
RN   [42]
RP   INTERACTION OF CAPSID-NUCLEOCAPSID COMPLEX WITH HUMAN PDZD8.
RX   PubMed=24554657; DOI=10.1128/jvi.02945-13;
RA   Guth C.A., Sodroski J.;
RT   "Contribution of PDZD8 to stabilization of the human immunodeficiency virus
RT   type 1 capsid.";
RL   J. Virol. 88:4612-4623(2014).
RN   [43]
RP   INTERACTION OF MATRIX PROTEIN P17 WITH RAT CALM1.
RX   PubMed=24500712; DOI=10.1074/jbc.m113.543694;
RA   Vlach J., Samal A.B., Saad J.S.;
RT   "Solution structure of calmodulin bound to the binding domain of the HIV-1
RT   matrix protein.";
RL   J. Biol. Chem. 289:8697-8705(2014).
RN   [44]
RP   FUNCTION (PROTEASE), AND CATALYTIC ACTIVITY (PROTEASE).
RX   PubMed=32053707; DOI=10.1371/journal.ppat.1008305;
RA   Jurczyszak D., Zhang W., Terry S.N., Kehrer T., Bermudez Gonzalez M.C.,
RA   McGregor E., Mulder L.C.F., Eckwahl M.J., Pan T., Simon V.;
RT   "HIV protease cleaves the antiviral m6A reader protein YTHDF3 in the viral
RT   particle.";
RL   PLoS Pathog. 16:e1008305-e1008305(2020).
RN   [45]
RP   FUNCTION (PROTEASE), CATALYTIC ACTIVITY (PROTEASE), ACTIVE SITE (PROTEASE),
RP   AND MUTAGENESIS OF ASP-513.
RX   PubMed=33542150; DOI=10.1126/science.abe1707;
RA   Wang Q., Gao H., Clark K.M., Mugisha C.S., Davis K., Tang J.P.,
RA   Harlan G.H., DeSelm C.J., Presti R.M., Kutluay S.B., Shan L.;
RT   "CARD8 is an inflammasome sensor for HIV-1 protease activity.";
RL   Science 0:0-0(2021).
RN   [46]
RP   REVIEW.
RX   PubMed=8791726; DOI=10.1007/978-3-642-80145-7_4;
RA   Vogt V.M.;
RT   "Proteolytic processing and particle maturation.";
RL   Curr. Top. Microbiol. Immunol. 214:95-131(1996).
RN   [47]
RP   REVIEW.
RX   PubMed=9878383; DOI=10.1006/jmbi.1998.2354;
RA   Turner B.G., Summers M.F.;
RT   "Structural biology of HIV.";
RL   J. Mol. Biol. 285:1-32(1999).
RN   [48]
RP   REVIEW.
RX   PubMed=11700285; DOI=10.1146/annurev.genet.35.102401.090551;
RA   Negroni M., Buc H.;
RT   "Mechanisms of retroviral recombination.";
RL   Annu. Rev. Genet. 35:275-302(2001).
RN   [49]
RP   REVIEW.
RX   PubMed=11983066; DOI=10.1186/gb-2002-3-4-reviews3006;
RA   Dunn B.M., Goodenow M.M., Gustchina A., Wlodawer A.;
RT   "Retroviral proteases.";
RL   Genome Biol. 3:REVIEWS3006.1-REVIEWS3006.7(2002).
RN   [50]
RP   REVIEW.
RX   PubMed=12873766; DOI=10.1016/s0005-2736(03)00163-9;
RA   Scarlata S., Carter C.;
RT   "Role of HIV-1 Gag domains in viral assembly.";
RL   Biochim. Biophys. Acta 1614:62-72(2003).
RN   [51]
RP   REVIEW.
RX   PubMed=15353349; DOI=10.2741/1472;
RA   Turlure F., Devroe E., Silver P.A., Engelman A.;
RT   "Human cell proteins and human immunodeficiency virus DNA integration.";
RL   Front. Biosci. 9:3187-3208(2004).
RN   [52]
RP   REVIEW.
RX   PubMed=16815734; DOI=10.1016/j.mib.2006.06.011;
RA   Sokolskaja E., Luban J.;
RT   "Cyclophilin, TRIM5, and innate immunity to HIV-1.";
RL   Curr. Opin. Microbiol. 9:404-408(2006).
RN   [53]
RP   REVIEW.
RX   PubMed=21762797; DOI=10.1016/j.jmb.2011.04.015;
RA   Chukkapalli V., Ono A.;
RT   "Molecular determinants that regulate plasma membrane association of HIV-1
RT   Gag.";
RL   J. Mol. Biol. 410:512-524(2011).
RN   [54]
RP   REVIEW.
RX   PubMed=24907482; DOI=10.1016/j.virusres.2014.05.011;
RA   Darlix J.L., de Rocquigny H., Mauffret O., Mely Y.;
RT   "Retrospective on the all-in-one retroviral nucleocapsid protein.";
RL   Virus Res. 193:2-15(2014).
RN   [55]
RP   REVIEW.
RX   PubMed=24933691; DOI=10.1016/j.tim.2014.04.012;
RA   Tedbury P.R., Freed E.O.;
RT   "The role of matrix in HIV-1 envelope glycoprotein incorporation.";
RL   Trends Microbiol. 22:372-378(2014).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 489-587.
RX   PubMed=2682266; DOI=10.1038/342299a0;
RA   Lapatto R., Blundell T., Hemmings A., Overington J., Wilderspin A.,
RA   Wood S., Merson J.R., Whittle P.J., Danley D.E., Geoghegan K.F.,
RA   Hawrylik S.J., Lee S.E., Scheld K.G., Hobart P.M.;
RT   "X-ray analysis of HIV-1 proteinase at 2.7-A resolution confirms structural
RT   homology among retroviral enzymes.";
RL   Nature 342:299-302(1989).
RN   [57]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 489-587 IN COMPLEX WITH THE
RP   INHIBITOR RO 32-8959.
RX   PubMed=1956054; DOI=10.1021/jm00115a028;
RA   Krohn A., Redshaw S., Ritchie J.C., Graves B.J., Hatada M.H.;
RT   "Novel binding mode of highly potent HIV-proteinase inhibitors
RT   incorporating the (R)-hydroxyethylamine isostere.";
RL   J. Med. Chem. 34:3340-3342(1991).
RN   [58]
RP   STRUCTURE BY NMR OF 390-406.
RX   PubMed=1959614; DOI=10.1016/0014-5793(91)80825-n;
RA   Omichinski J.G., Clore G.M., Sakaguchi K., Appella E., Gronenborn A.M.;
RT   "Structural characterization of a 39-residue synthetic peptide containing
RT   the two zinc binding domains from the HIV-1 p7 nucleocapsid protein by CD
RT   and NMR spectroscopy.";
RL   FEBS Lett. 292:25-30(1991).
RN   [59]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 489-587 IN COMPLEX WITH A
RP   DIHYDROXYETHYLENE-CONTAINING INHIBITOR.
RX   PubMed=1304383; DOI=10.1002/pro.5560010811;
RA   Thanki N., Rao J.K., Foundling S.I., Howe W.J., Moon J.B., Hui J.O.,
RA   Tomasselli A.G., Heinrikson R.L., Thaisrivongs S., Wlodawer A.;
RT   "Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene-
RT   containing inhibitor: comparisons with molecular modeling.";
RL   Protein Sci. 1:1061-1072(1992).
RN   [60]
RP   STRUCTURE BY NMR OF 390-430.
RX   PubMed=8289249; DOI=10.1016/s0022-2836(05)80033-6;
RA   Morellet N., de Rocquigny H., Mely Y., Jullian N., Demene H., Ottmann M.,
RA   Gerard D., Darlix J.L., Fournie-Zaluski M.-C., Roques B.P.;
RT   "Conformational behaviour of the active and inactive forms of the
RT   nucleocapsid NCp7 of HIV-1 studied by 1H NMR.";
RL   J. Mol. Biol. 235:287-301(1994).
RN   [61]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 489-587 IN COMPLEX WITH THE
RP   INHIBITOR XK263.
RX   PubMed=8278812; DOI=10.1126/science.8278812;
RA   Lam P.Y.S., Jadhav P.K., Eyermann C.J., Hodge C.N., Ru Y., Bacheler L.T.,
RA   Meek J.L., Otto M.J., Rayner M.M., Wong Y.N., Chang C.-H., Weber P.C.,
RA   Jackson D.A., Sharpe T.R., Erickson-Viitanen S.;
RT   "Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV
RT   protease inhibitors.";
RL   Science 263:380-384(1994).
RN   [62]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 588-1147.
RX   PubMed=7523679; DOI=10.1006/jmbi.1994.1604;
RA   Stammers D.K., Somers D.O., Ross C.K., Kirby I., Ray P.H., Wilson J.E.,
RA   Norman M., Ren J.S., Esnouf R.M., Garman E.F., Jones E.Y., Stuart D.I.;
RT   "Crystals of HIV-1 reverse transcriptase diffracting to 2.2 A resolution.";
RL   J. Mol. Biol. 242:586-588(1994).
RN   [63]
RP   STRUCTURE BY NMR OF 1-132.
RX   PubMed=8654825; DOI=10.1042/bst0230725;
RA   Matthews S., Barlow P., Clark N., Kingsman S., Kingsman A., Campbell I.;
RT   "Refined solution structure of p17, the HIV matrix protein.";
RL   Biochem. Soc. Trans. 23:725-729(1995).
RN   [64]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 588-1027.
RX   PubMed=8535785; DOI=10.1016/s0969-2126(01)00226-x;
RA   Ren J.S., Esnouf R.M., Hopkins A.L., Ross C.K., Jones E.Y., Stammers D.K.,
RA   Stuart D.I.;
RT   "The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO:
RT   lessons for inhibitor design.";
RL   Structure 3:915-926(1995).
RN   [65]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 588-1147.
RX   PubMed=7540935; DOI=10.1038/nsb0495-303;
RA   Esnouf R.M., Ren J.S., Ross C.K., Jones E.Y., Stammers D.K., Stuart D.I.;
RT   "Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside
RT   inhibitors.";
RL   Nat. Struct. Biol. 2:303-308(1995).
RN   [66]
RP   X-RAY CRYSTALLOGRAPHY (2.55 ANGSTROMS) OF 588-1027.
RX   PubMed=8648598; DOI=10.1021/jm960056x;
RA   Hopkins A.L., Ren J.S., Esnouf R.M., Willcox B.E., Jones E.Y., Ross C.K.,
RA   Miyasaka T., Walker R.T., Tanaka H., Stammers D.K., Stuart D.I.;
RT   "Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT
RT   series reveal conformational changes relevant to the design of potent non-
RT   nucleoside inhibitors.";
RL   J. Med. Chem. 39:1589-1600(1996).
RN   [67]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 489-587 IN COMPLEX WITH COMPLEX
RP   WITH DMP450.
RX   PubMed=8807858; DOI=10.1016/s1074-5521(96)90110-6;
RA   Hodge C.N., Aldrich P.E., Bacheler L.T., Chang C.-H., Eyermann C.J.,
RA   Garber S.S., Grubb M., Jackson D.A., Jadhav P.K., Korant B.D., Lam P.Y.S.,
RA   Maurin M.B., Meek J.L., Otto M.J., Rayner M.M., Reid C., Sharpe T.R.,
RA   Shum L., Winslow D.L., Erickson-Viitanen S.;
RT   "Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency,
RT   resistance profile, human pharmacokinetics and X-ray crystal structure of
RT   DMP 450.";
RL   Chem. Biol. 3:301-314(1996).
RN   [68]
RP   STRUCTURE BY NMR OF 489-587 IN COMPLEX WITH THE INHIBITOR DMP323.
RX   PubMed=8868486; DOI=10.1002/pro.5560050311;
RA   Yamazaki T., Hinck A.P., Wang Y.X., Nicholson L.K., Torchia D.A.,
RA   Wingfield P., Stahl S.J., Kaufman J.D., Chang C.-H., Domaille P.J.,
RA   Lam P.Y.S.;
RT   "Three-dimensional solution structure of the HIV-1 protease complexed with
RT   DMP323, a novel cyclic urea-type inhibitor, determined by nuclear magnetic
RT   resonance spectroscopy.";
RL   Protein Sci. 5:495-506(1996).
RN   [69]
RP   X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 588-1130.
RX   PubMed=9108091; DOI=10.1073/pnas.94.8.3984;
RA   Esnouf R.M., Ren J.S., Hopkins A.L., Ross C.K., Jones E.Y., Stammers D.K.,
RA   Stuart D.I.;
RT   "Unique features in the structure of the complex between HIV-1 reverse
RT   transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain
RT   resistance mutations for this nonnucleoside inhibitor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:3984-3989(1997).
RN   [70]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 489-587.
RX   PubMed=9003516; DOI=10.1021/jm960586t;
RA   Jadhav P.K., Ala P.J., Woerner F.J., Chang C.-H., Garber S.S., Anton E.D.,
RA   Bacheler L.T.;
RT   "Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency
RT   against both wild type and protease inhibitor resistant mutants of HIV.";
RL   J. Med. Chem. 40:181-191(1997).
RN   [71]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 489-587 IN COMPLEX WITH THE
RP   INHIBITOR LP-130.
RX   PubMed=9827997; DOI=10.1002/pro.5560071108;
RA   Kervinen J., Lubkowski J., Zdanov A., Bhatt D., Dunn B.M., Hui K.Y.,
RA   Powell D.J., Kay J., Wlodawer A., Gustchina A.;
RT   "Toward a universal inhibitor of retroviral proteases: comparative analysis
RT   of the interactions of LP-130 complexed with proteases from HIV-1, FIV, and
RT   EIAV.";
RL   Protein Sci. 7:2314-2323(1998).
RN   [72]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 489-587.
RX   PubMed=9554878; DOI=10.1021/jm970524i;
RA   Jadhav P.K., Woerner F.J., Lam P.Y., Hodge C.N., Eyermann C.J., Man H.W.,
RA   Daneker W.F., Bacheler L.T., Rayner M.M., Meek J.L., Erickson-Viitanen S.,
RA   Jackson D.A., Calabrese J.C., Schadt M.C., Chang C.-H.;
RT   "Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis,
RT   structure-activity relationships, and X-ray crystal structure studies.";
RL   J. Med. Chem. 41:1446-1455(1998).
RN   [73]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 489-587.
RX   PubMed=9790666; DOI=10.1021/bi980386e;
RA   Ala P.J., Huston E.E., Klabe R.M., Jadhav P.K., Lam P.Y.S., Chang C.-H.;
RT   "Counteracting HIV-1 protease drug resistance: structural analysis of
RT   mutant proteases complexed with XV638 and SD146, cyclic urea amides with
RT   broad specificities.";
RL   Biochemistry 37:15042-15049(1998).
RN   [74]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 489-587.
RX   PubMed=9575185; DOI=10.1074/jbc.273.20.12325;
RA   Ala P.J., DeLoskey R.J., Huston E.E., Jadhav P.K., Lam P.Y.S.,
RA   Eyermann C.J., Hodge C.N., Schadt M.C., Lewandowski F.A., Weber P.C.,
RA   McCabe D.D., Duke J.L., Chang C.-H.;
RT   "Molecular recognition of cyclic urea HIV-1 protease inhibitors.";
RL   J. Biol. Chem. 273:12325-12331(1998).
RN   [75]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 490-587 IN COMPLEX WITH A
RP   TRIPEPTIDE INHIBITOR.
RX   PubMed=9485357; DOI=10.1021/bi972059x;
RA   Louis J.M., Dyda F., Nashed N.T., Kimmel A.R., Davies D.R.;
RT   "Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit
RT   the HIV-1 protease.";
RL   Biochemistry 37:2105-2110(1998).
RN   [76]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 588-1130.
RX   PubMed=9689112; DOI=10.1073/pnas.95.16.9518;
RA   Ren J.S., Esnouf R.M., Hopkins A.L., Jones E.Y., Kirby I., Keeling J.,
RA   Ross C.K., Larder B.A., Stuart D.I., Stammers D.K.;
RT   "3'-azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse
RT   transcriptase can induce long range conformational changes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:9518-9523(1998).
RN   [77]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 588-1147 IN COMPLEX WITH
RP   CARBOXANILIDE DERIVATIVES.
RX   PubMed=9772165; DOI=10.1021/bi981309m;
RA   Ren J.S., Esnouf R.M., Hopkins A.L., Warren J., Balzarini J., Stuart D.I.,
RA   Stammers D.K.;
RT   "Crystal structures of HIV-1 reverse transcriptase in complex with
RT   carboxanilide derivatives.";
RL   Biochemistry 37:14394-14403(1998).
RN   [78]
RP   X-RAY CRYSTALLOGRAPHY (1.88 ANGSTROMS) OF 501-599.
RX   PubMed=10429209; DOI=10.1046/j.1432-1327.1999.00514.x;
RA   Mahalingam B., Louis J.M., Reed C.C., Adomat J.M., Krouse J., Wang Y.-F.,
RA   Harrison R.W., Weber I.T.;
RT   "Structural and kinetic analysis of drug resistant mutants of HIV-1
RT   protease.";
RL   Eur. J. Biochem. 263:238-245(1999).
RN   [79]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 1199-1435.
RX   PubMed=10890912; DOI=10.1073/pnas.150220297;
RA   Chen J.C., Krucinski J., Miercke L.J., Finer-Moore J.S., Tang A.H.,
RA   Leavitt A.D., Stroud R.M.;
RT   "Crystal structure of the HIV-1 integrase catalytic core and C-terminal
RT   domains: a model for viral DNA binding.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:8233-8238(2000).
RN   [80]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 489-587.
RX   PubMed=11170214;
RX   DOI=10.1002/1097-0134(20010401)43:1<57::aid-prot1017>3.0.co;2-d;
RA   Pillai B., Kannan K.K., Hosur M.V.;
RT   "1.9 A X-ray study shows closed flap conformation in crystals of tethered
RT   HIV-1 PR.";
RL   Proteins 43:57-64(2001).
RN   [81]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 588-1147 IN COMPLEX WITH
RP   INHIBITORS.
RX   PubMed=11575933; DOI=10.1006/jmbi.2001.4988;
RA   Ren J.S., Nichols C.E., Bird L.E., Chamberlain P.P., Weaver K.L.,
RA   Short S.A., Stuart D.I., Stammers D.K.;
RT   "Structural mechanisms of drug resistance for mutations at codons 181 and
RT   188 in HIV-1 reverse transcriptase and the improved resilience of second
RT   generation non-nucleoside inhibitors.";
RL   J. Mol. Biol. 312:795-805(2001).
RN   [82]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 489-587.
RX   PubMed=12051725; DOI=10.1016/s0006-291x(02)00482-5;
RA   Kumar M., Kannan K.K., Hosur M.V., Bhavesh N.S., Chatterjee A., Mittal R.,
RA   Hosur R.V.;
RT   "Effects of remote mutation on the autolysis of HIV-1 PR: X-ray and NMR
RT   investigations.";
RL   Biochem. Biophys. Res. Commun. 294:395-401(2002).
RN   [83]
RP   STRUCTURE BY NMR OF 1014-1147.
RX   PubMed=12534276; DOI=10.1021/bi0204894;
RA   Pari K., Mueller G.A., DeRose E.F., Kirby T.W., London R.E.;
RT   "Solution structure of the RNase H domain of the HIV-1 reverse
RT   transcriptase in the presence of magnesium.";
RL   Biochemistry 42:639-650(2003).
RN   [84]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 588-1147 IN COMPLEX WITH
RP   INHIBITORS.
RX   PubMed=15095972; DOI=10.1016/j.jmb.2003.12.055;
RA   Ren J.S., Nichols C.E., Chamberlain P.P., Weaver K.L., Short S.A.,
RA   Stammers D.K.;
RT   "Crystal structures of HIV-1 reverse transcriptases mutated at codons 100,
RT   106 and 108 and mechanisms of resistance to non-nucleoside inhibitors.";
RL   J. Mol. Biol. 336:569-578(2004).
RN   [85]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 588-1147 IN COMPLEX WITH
RP   INHIBITORS.
RX   PubMed=15537347; DOI=10.1021/jm040072r;
RA   Freeman G.A., Andrews C.W. III, Hopkins A.L., Lowell G.S., Schaller L.T.,
RA   Cowan J.R., Gonzales S.S., Koszalka G.W., Hazen R.J., Boone L.R.,
RA   Ferris R.G., Creech K.L., Roberts G.B., Short S.A., Weaver K.L.,
RA   Reynolds D.J., Milton J., Ren J.S., Stuart D.I., Stammers D.K., Chan J.H.;
RT   "Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with
RT   improved drug resistance properties. 2.";
RL   J. Med. Chem. 47:5923-5936(2004).
CC   -!- FUNCTION: [Gag-Pol polyprotein]: Mediates, with Gag polyprotein, the
CC       essential events in virion assembly, including binding the plasma
CC       membrane, making the protein-protein interactions necessary to create
CC       spherical particles, recruiting the viral Env proteins, and packaging
CC       the genomic RNA via direct interactions with the RNA packaging sequence
CC       (Psi). Gag-Pol polyprotein may regulate its own translation, by the
CC       binding genomic RNA in the 5'-UTR. At low concentration, the
CC       polyprotein would promote translation, whereas at high concentration,
CC       the polyprotein would encapsidate genomic RNA and then shut off
CC       translation.
CC   -!- FUNCTION: [Matrix protein p17]: Targets the polyprotein to the plasma
CC       membrane via a multipartite membrane-binding signal, that includes its
CC       myristoylated N-terminus (By similarity). Matrix protein is part of the
CC       pre-integration complex. Implicated in the release from host cell
CC       mediated by Vpu. Binds to RNA (By similarity).
CC       {ECO:0000250|UniProtKB:P12497}.
CC   -!- FUNCTION: [Capsid protein p24]: Forms the conical core that
CC       encapsulates the genomic RNA-nucleocapsid complex in the virion
CC       (PubMed:8648689). Most core are conical, with only 7% tubular. The core
CC       is constituted by capsid protein hexamer subunits. The core is
CC       disassembled soon after virion entry (PubMed:12660176). Host
CC       restriction factors such as monkey TRIM5-alpha or TRIMCyp bind
CC       retroviral capsids and cause premature capsid disassembly, leading to
CC       blocks in reverse transcription. Capsid restriction by TRIM5 is one of
CC       the factors which restricts HIV-1 to the human species
CC       (PubMed:23785198). Host PIN1 apparently facilitates the virion
CC       uncoating (By similarity). On the other hand, interactions with PDZD8
CC       or CYPA stabilize the capsid (PubMed:24554657).
CC       {ECO:0000250|UniProtKB:P12497, ECO:0000269|PubMed:12660176,
CC       ECO:0000269|PubMed:23785198, ECO:0000269|PubMed:24554657,
CC       ECO:0000269|PubMed:8648689}.
CC   -!- FUNCTION: [Nucleocapsid protein p7]: Encapsulates and protects viral
CC       dimeric unspliced genomic RNA (gRNA). Binds these RNAs through its zinc
CC       fingers. Acts as a nucleic acid chaperone which is involved in
CC       rearangement of nucleic acid secondary structure during gRNA
CC       retrotranscription. Also facilitates template switch leading to
CC       recombination. As part of the polyprotein, participates in gRNA
CC       dimerization, packaging, tRNA incorporation and virion assembly.
CC       {ECO:0000269|PubMed:11044125, ECO:0000269|PubMed:17070549,
CC       ECO:0000269|PubMed:18343475, ECO:0000269|PubMed:20828778,
CC       ECO:0000269|PubMed:9931246}.
CC   -!- FUNCTION: [Protease]: Aspartyl protease that mediates proteolytic
CC       cleavages of Gag and Gag-Pol polyproteins during or shortly after the
CC       release of the virion from the plasma membrane (PubMed:11932404,
CC       PubMed:9573231). Cleavages take place as an ordered, step-wise cascade
CC       to yield mature proteins (PubMed:11932404, PubMed:9573231). This
CC       process is called maturation (PubMed:11932404, PubMed:9573231).
CC       Displays maximal activity during the budding process just prior to
CC       particle release from the cell (PubMed:11932404, PubMed:9573231). Also
CC       cleaves Nef and Vif, probably concomitantly with viral structural
CC       proteins on maturation of virus particles (PubMed:7835426). Hydrolyzes
CC       host EIF4GI and PABP1 in order to shut off the capped cellular mRNA
CC       translation. The resulting inhibition of cellular protein synthesis
CC       serves to ensure maximal viral gene expression and to evade host immune
CC       response (PubMed:12660176, PubMed:19914170). Also mediates cleavage of
CC       host YTHDF3 (PubMed:32053707). Mediates cleavage of host CARD8, thereby
CC       activating the CARD8 inflammasome, leading to the clearance of latent
CC       HIV-1 in patient CD4(+) T-cells after viral reactivation; in contrast,
CC       HIV-1 can evade CARD8-sensing when its protease remains inactive in
CC       infected cells prior to viral budding (PubMed:33542150).
CC       {ECO:0000255|PROSITE-ProRule:PRU00275, ECO:0000269|PubMed:12505164,
CC       ECO:0000269|PubMed:19956697, ECO:0000269|PubMed:32053707,
CC       ECO:0000269|PubMed:33542150, ECO:0000269|PubMed:7835426}.
CC   -!- FUNCTION: [Reverse transcriptase/ribonuclease H]: Multifunctional
CC       enzyme that converts the viral RNA genome into dsDNA in the cytoplasm,
CC       shortly after virus entry into the cell. This enzyme displays a DNA
CC       polymerase activity that can copy either DNA or RNA templates, and a
CC       ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-
CC       DNA heteroduplexes in a partially processive 3' to 5' endonucleasic
CC       mode. Conversion of viral genomic RNA into dsDNA requires many steps. A
CC       tRNA(3)-Lys binds to the primer-binding site (PBS) situated at the 5'-
CC       end of the viral RNA. RT uses the 3' end of the tRNA primer to perform
CC       a short round of RNA-dependent minus-strand DNA synthesis. The reading
CC       proceeds through the U5 region and ends after the repeated (R) region
CC       which is present at both ends of viral RNA. The portion of the RNA-DNA
CC       heteroduplex is digested by the RNase H, resulting in a ssDNA product
CC       attached to the tRNA primer. This ssDNA/tRNA hybridizes with the
CC       identical R region situated at the 3' end of viral RNA. This template
CC       exchange, known as minus-strand DNA strong stop transfer, can be either
CC       intra- or intermolecular. RT uses the 3' end of this newly synthesized
CC       short ssDNA to perform the RNA-dependent minus-strand DNA synthesis of
CC       the whole template. RNase H digests the RNA template except for two
CC       polypurine tracts (PPTs) situated at the 5'-end and near the center of
CC       the genome. It is not clear if both polymerase and RNase H activities
CC       are simultaneous. RNase H probably can proceed both in a polymerase-
CC       dependent (RNA cut into small fragments by the same RT performing DNA
CC       synthesis) and a polymerase-independent mode (cleavage of remaining RNA
CC       fragments by free RTs). Secondly, RT performs DNA-directed plus-strand
CC       DNA synthesis using the PPTs that have not been removed by RNase H as
CC       primers. PPTs and tRNA primers are then removed by RNase H. The 3' and
CC       5' ssDNA PBS regions hybridize to form a circular dsDNA intermediate.
CC       Strand displacement synthesis by RT to the PBS and PPT ends produces a
CC       blunt ended, linear dsDNA copy of the viral genome that includes long
CC       terminal repeats (LTRs) at both ends. {ECO:0000269|PubMed:16221683}.
CC   -!- FUNCTION: [Integrase]: Catalyzes viral DNA integration into the host
CC       chromosome, by performing a series of DNA cutting and joining
CC       reactions. This enzyme activity takes place after virion entry into a
CC       cell and reverse transcription of the RNA genome in dsDNA. The first
CC       step in the integration process is 3' processing. This step requires a
CC       complex comprising the viral genome, matrix protein, Vpr and integrase.
CC       This complex is called the pre-integration complex (PIC). The integrase
CC       protein removes 2 nucleotides from each 3' end of the viral DNA,
CC       leaving recessed CA OH's at the 3' ends. In the second step, the PIC
CC       enters cell nucleus. This process is mediated through integrase and Vpr
CC       proteins, and allows the virus to infect a non dividing cell. This
CC       ability to enter the nucleus is specific of lentiviruses, other
CC       retroviruses cannot and rely on cell division to access cell
CC       chromosomes. In the third step, termed strand transfer, the integrase
CC       protein joins the previously processed 3' ends to the 5' ends of
CC       strands of target cellular DNA at the site of integration. The 5'-ends
CC       are produced by integrase-catalyzed staggered cuts, 5 bp apart. A Y-
CC       shaped, gapped, recombination intermediate results, with the 5'-ends of
CC       the viral DNA strands and the 3' ends of target DNA strands remaining
CC       unjoined, flanking a gap of 5 bp. The last step is viral DNA
CC       integration into host chromosome. This involves host DNA repair
CC       synthesis in which the 5 bp gaps between the unjoined strands are
CC       filled in and then ligated. Since this process occurs at both cuts
CC       flanking the HIV genome, a 5 bp duplication of host DNA is produced at
CC       the ends of HIV-1 integration. Alternatively, Integrase may catalyze
CC       the excision of viral DNA just after strand transfer, this is termed
CC       disintegration. {ECO:0000269|PubMed:20554775,
CC       ECO:0000269|PubMed:2349226}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Specific for a P1 residue that is hydrophobic, and P1'
CC         variable, but often Pro.; EC=3.4.23.16;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU00275,
CC         ECO:0000269|PubMed:32053707, ECO:0000269|PubMed:33542150};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Endohydrolysis of RNA in RNA/DNA hybrids. Three different
CC         cleavage modes: 1. sequence-specific internal cleavage of RNA. Human
CC         immunodeficiency virus type 1 and Moloney murine leukemia virus
CC         enzymes prefer to cleave the RNA strand one nucleotide away from the
CC         RNA-DNA junction. 2. RNA 5'-end directed cleavage 13-19 nucleotides
CC         from the RNA end. 3. DNA 3'-end directed cleavage 15-20 nucleotides
CC         away from the primer terminus.; EC=3.1.26.13;
CC         Evidence={ECO:0000250|UniProtKB:P03366};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3'-end directed exonucleolytic cleavage of viral RNA-DNA
CC         hybrid.; EC=3.1.13.2;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) +
CC         diphosphate; Xref=Rhea:RHEA:22508, Rhea:RHEA-COMP:17339, Rhea:RHEA-
CC         COMP:17340, ChEBI:CHEBI:33019, ChEBI:CHEBI:61560, ChEBI:CHEBI:173112;
CC         EC=2.7.7.49; Evidence={ECO:0000255|PROSITE-ProRule:PRU00405};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) +
CC         diphosphate; Xref=Rhea:RHEA:22508, Rhea:RHEA-COMP:17339, Rhea:RHEA-
CC         COMP:17340, ChEBI:CHEBI:33019, ChEBI:CHEBI:61560, ChEBI:CHEBI:173112;
CC         EC=2.7.7.7; Evidence={ECO:0000255|PROSITE-ProRule:PRU00405};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Note=Binds 2 magnesium ions for reverse transcriptase polymerase
CC       activity. {ECO:0000250};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Note=Binds 2 magnesium ions for ribonuclease H (RNase H) activity.
CC       Substrate-binding is a precondition for magnesium binding.
CC       {ECO:0000250};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Note=Magnesium ions are required for integrase activity. Binds at least
CC       1, maybe 2 magnesium ions. {ECO:0000250};
CC   -!- ACTIVITY REGULATION: Protease: The viral protease is inhibited by many
CC       synthetic protease inhibitors (PIs), such as amprenavir, atazanavir,
CC       indinavir, loprinavir, nelfinavir, ritonavir and saquinavir. Use of
CC       protease inhibitors in tritherapy regimens permit more ambitious
CC       therapeutic strategies. Reverse transcriptase/ribonuclease H: RT can be
CC       inhibited either by nucleoside RT inhibitors (NRTIs) or by non
CC       nucleoside RT inhibitors (NNRTIs). NRTIs act as chain terminators,
CC       whereas NNRTIs inhibit DNA polymerization by binding a small
CC       hydrophobic pocket near the RT active site and inducing an allosteric
CC       change in this region. Classical NRTIs are abacavir, adefovir (PMEA),
CC       didanosine (ddI), lamivudine (3TC), stavudine (d4T), tenofovir (PMPA),
CC       zalcitabine (ddC), and zidovudine (AZT). Classical NNRTIs are
CC       atevirdine (BHAP U-87201E), delavirdine, efavirenz (DMP-266), emivirine
CC       (I-EBU), and nevirapine (BI-RG-587). The tritherapies used as a basic
CC       effective treatment of AIDS associate two NRTIs and one NNRTI.
CC   -!- SUBUNIT: [Matrix protein p17]: Homotrimer; further assembles as
CC       hexamers of trimers (PubMed:19327811). Interacts with gp41 (via C-
CC       terminus) (By similarity). Interacts with host CALM1; this interaction
CC       induces a conformational change in the Matrix protein, triggering
CC       exposure of the myristate group (PubMed:24500712). Interacts with host
CC       AP3D1; this interaction allows the polyprotein trafficking to
CC       multivesicular bodies during virus assembly (By similarity). Part of
CC       the pre-integration complex (PIC) which is composed of viral genome,
CC       matrix protein, Vpr and integrase (By similarity).
CC       {ECO:0000250|UniProtKB:P12497, ECO:0000269|PubMed:19327811,
CC       ECO:0000269|PubMed:24500712}.
CC   -!- SUBUNIT: [Capsid protein p24]: Homodimer; the homodimer further
CC       multimerizes as homohexamers or homopentamers (PubMed:19914170).
CC       Interacts with human PPIA/CYPA (PubMed:9223641, PubMed:8513493); this
CC       interaction stabilizes the capsid. Interacts with human NUP153 (By
CC       similarity). Interacts with host PDZD8; this interaction stabilizes the
CC       capsid (PubMed:20573829). Interacts with monkey TRIM5; this interaction
CC       destabilizes the capsid (PubMed:23785198).
CC       {ECO:0000250|UniProtKB:P12497, ECO:0000269|PubMed:19914170,
CC       ECO:0000269|PubMed:20573829, ECO:0000269|PubMed:23785198,
CC       ECO:0000269|PubMed:8513493, ECO:0000269|PubMed:9223641}.
CC   -!- SUBUNIT: [Protease]: Homodimer, whose active site consists of two
CC       apposed aspartic acid residues (PubMed:2162350, PubMed:24132393).
CC       {ECO:0000269|PubMed:2162350, ECO:0000269|PubMed:24132393}.
CC   -!- SUBUNIT: [Reverse transcriptase/ribonuclease H]: Heterodimer of p66 RT
CC       and p51 RT (RT p66/p51) (PubMed:15183348). Heterodimerization of RT is
CC       essential for DNA polymerase activity (By similarity). The overall
CC       folding of the subdomains is similar in p66 RT and p51 RT but the
CC       spatial arrangements of the subdomains are dramatically different (By
CC       similarity). {ECO:0000250|UniProtKB:P03366,
CC       ECO:0000269|PubMed:15183348}.
CC   -!- SUBUNIT: [Integrase]: Homotetramer; may further associate as a
CC       homohexadecamer (By similarity). Part of the pre-integration complex
CC       (PIC) which is composed of viral genome, matrix protein, Vpr and
CC       integrase. Interacts with human SMARCB1/INI1 and human PSIP1/LEDGF
CC       isoform 1 (PubMed:7801128). Interacts with human KPNA3; this
CC       interaction might play a role in nuclear import of the pre-.
CC       integration complex (PubMed:19914170). Interacts with human NUP153;
CC       this interaction might play a role in nuclear import of the pre-
CC       integration complex (By similarity). {ECO:0000250|UniProtKB:P03367,
CC       ECO:0000250|UniProtKB:P12497, ECO:0000269|PubMed:19914170,
CC       ECO:0000269|PubMed:7801128}.
CC   -!- INTERACTION:
CC       P04585; P04585: gag-pol; NbExp=29; IntAct=EBI-3989067, EBI-3989067;
CC       P04585; P03366: gag-pol; Xeno; NbExp=2; IntAct=EBI-3989067, EBI-6164084;
CC       P04585; O75475: PSIP1; Xeno; NbExp=21; IntAct=EBI-3989067, EBI-1801773;
CC       P04585; P69718: rev; Xeno; NbExp=8; IntAct=EBI-3989067, EBI-8540156;
CC       PRO_0000042440; PRO_0000042440 [P04585]: gag-pol; NbExp=5; IntAct=EBI-2504097, EBI-2504097;
CC       PRO_0000042447; O00629: KPNA4; Xeno; NbExp=4; IntAct=EBI-9872653, EBI-396343;
CC       PRO_0000042447; O75475-1: PSIP1; Xeno; NbExp=2; IntAct=EBI-9872653, EBI-5279836;
CC       PRO_0000042447; Q12824: SMARCB1; Xeno; NbExp=3; IntAct=EBI-9872653, EBI-358419;
CC       PRO_0000042447; Q9Y5L0: TNPO3; Xeno; NbExp=6; IntAct=EBI-9872653, EBI-1042571;
CC   -!- SUBCELLULAR LOCATION: [Gag-Pol polyprotein]: Host cell membrane; Lipid-
CC       anchor {ECO:0000250|UniProtKB:P12493}. Host endosome, host
CC       multivesicular body {ECO:0000250|UniProtKB:P12493}. Note=These
CC       locations are linked to virus assembly sites. The main location is the
CC       cell membrane, but under some circumstances, late endosomal
CC       compartments can serve as productive sites for virion assembly.
CC       {ECO:0000250|UniProtKB:P12493}.
CC   -!- SUBCELLULAR LOCATION: [Matrix protein p17]: Virion membrane; Lipid-
CC       anchor {ECO:0000305}. Host nucleus {ECO:0000250}. Host cytoplasm
CC       {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Capsid protein p24]: Virion {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: [Nucleocapsid protein p7]: Virion {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: [Reverse transcriptase/ribonuclease H]: Virion
CC       {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: [Integrase]: Virion {ECO:0000305}. Host nucleus
CC       {ECO:0000269|PubMed:18722123}. Host cytoplasm {ECO:0000305}.
CC       Note=Nuclear at initial phase, cytoplasmic at assembly. {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Ribosomal frameshifting; Named isoforms=2;
CC         Comment=Translation results in the formation of the Gag polyprotein
CC         most of the time. Ribosomal frameshifting at the gag-pol genes
CC         boundary occurs at low frequency and produces the Gag-Pol
CC         polyprotein. This strategy of translation probably allows the virus
CC         to modulate the quantity of each viral protein. Maintenance of a
CC         correct Gag to Gag-Pol ratio is essential for RNA dimerization and
CC         viral infectivity.;
CC       Name=Gag-Pol polyprotein;
CC         IsoId=P04585-1; Sequence=Displayed;
CC       Name=Gag polyprotein;
CC         IsoId=P04591-1; Sequence=External;
CC   -!- DOMAIN: [Reverse transcriptase/ribonuclease H]: RT is structured in
CC       five subdomains: finger, palm, thumb, connection and RNase H. Within
CC       the palm subdomain, the 'primer grip' region is thought to be involved
CC       in the positioning of the primer terminus for accommodating the
CC       incoming nucleotide. The RNase H domain stabilizes the association of
CC       RT with primer-template (By similarity). {ECO:0000250}.
CC   -!- DOMAIN: [Reverse transcriptase/ribonuclease H]: The tryptophan repeat
CC       motif is involved in RT p66/p51 dimerization.
CC   -!- DOMAIN: [Integrase]: The core domain contains the D-x(n)-D-x(35)-E
CC       motif, named for the phylogenetically conserved glutamic acid and
CC       aspartic acid residues and the invariant 35 amino acid spacing between
CC       the second and third acidic residues. Each acidic residue of the
CC       D,D(35)E motif is independently essential for the 3'-processing and
CC       strand transfer activities of purified integrase protein.
CC   -!- PTM: [Gag-Pol polyprotein]: Specific enzymatic cleavages by the viral
CC       protease yield mature proteins. The protease is released by
CC       autocatalytic cleavage. The polyprotein is cleaved during and after
CC       budding, this process is termed maturation. Proteolytic cleavage of p66
CC       RT removes the RNase H domain to yield the p51 RT subunit. Nucleocapsid
CC       protein p7 might be further cleaved after virus entry.
CC       {ECO:0000255|PROSITE-ProRule:PRU00405, ECO:0000269|PubMed:10494040,
CC       ECO:0000269|PubMed:12477841, ECO:0000269|PubMed:15065874}.
CC   -!- PTM: [Matrix protein p17]: Tyrosine phosphorylated presumably in the
CC       virion by a host kinase. Phosphorylation is apparently not a major
CC       regulator of membrane association (PubMed:17656588).
CC       {ECO:0000269|PubMed:17656588}.
CC   -!- PTM: [Capsid protein p24]: Phosphorylated possibly by host MAPK1; this
CC       phosphorylation is necessary for Pin1-mediated virion uncoating.
CC       {ECO:0000250|UniProtKB:P12493}.
CC   -!- PTM: [Nucleocapsid protein p7]: Methylated by host PRMT6, impairing its
CC       function by reducing RNA annealing and the initiation of reverse
CC       transcription. {ECO:0000250|UniProtKB:P03366}.
CC   -!- MISCELLANEOUS: [Reverse transcriptase/ribonuclease H]: Error-prone
CC       enzyme that lacks a proof-reading function. High mutations rate is a
CC       direct consequence of this characteristic. RT also displays frequent
CC       template switching leading to high recombination rate. Recombination
CC       mostly occurs between homologous regions of the two copackaged RNA
CC       genomes. If these two RNA molecules derive from different viral
CC       strains, reverse transcription will give rise to highly recombinated
CC       proviral DNAs.
CC   -!- MISCELLANEOUS: HIV-1 lineages are divided in three main groups, M (for
CC       Major), O (for Outlier), and N (for New, or Non-M, Non-O). The vast
CC       majority of strains found worldwide belong to the group M. Group O
CC       seems to be endemic to and largely confined to Cameroon and neighboring
CC       countries in West Central Africa, where these viruses represent a small
CC       minority of HIV-1 strains. The group N is represented by a limited
CC       number of isolates from Cameroonian persons. The group M is further
CC       subdivided in 9 clades or subtypes (A to D, F to H, J and K).
CC   -!- MISCELLANEOUS: Resistance to inhibitors associated with mutations are
CC       observed both in viral protease and in reverse transcriptase. Most of
CC       the time, single mutations confer only a modest reduction in drug
CC       susceptibility. Combination of several mutations is usually required to
CC       develop a high-level drug resistance. These mutations are predominantly
CC       found in clade B viruses and not in other genotypes. They are listed in
CC       this entry which is a representative of clade B.
CC   -!- MISCELLANEOUS: [Isoform Gag-Pol polyprotein]: Produced by -1 ribosomal
CC       frameshifting.
CC   -!- WEB RESOURCE: Name=HIV drug resistance mutations;
CC       URL="https://www.iasusa.org/hiv-drug-resistance/hiv-drug-resistance-mutations/";
CC   -!- WEB RESOURCE: Name=hivdb; Note=HIV drug resistance database;
CC       URL="https://hivdb.stanford.edu";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; K03455; AAB50259.1; ALT_SEQ; Genomic_RNA.
DR   EMBL; AF033819; AAC82598.2; ALT_SEQ; Genomic_RNA.
DR   RefSeq; NP_057849.4; NC_001802.1.
DR   PDB; 1A30; X-ray; 2.00 A; A/B=489-587.
DR   PDB; 1BV7; X-ray; 2.00 A; A/B=489-587.
DR   PDB; 1BV9; X-ray; 2.00 A; A/B=489-587.
DR   PDB; 1BVE; NMR; -; A/B=489-587.
DR   PDB; 1BVG; NMR; -; A/B=489-587.
DR   PDB; 1BWA; X-ray; 1.90 A; A/B=489-587.
DR   PDB; 1BWB; X-ray; 1.80 A; A/B=489-587.
DR   PDB; 1C0T; X-ray; 2.70 A; A=588-1147, B=588-1027.
DR   PDB; 1C0U; X-ray; 2.52 A; A=588-1147, B=588-1027.
DR   PDB; 1C1B; X-ray; 2.50 A; A=588-1147, B=588-1027.
DR   PDB; 1C1C; X-ray; 2.50 A; A=588-1147, B=588-1027.
DR   PDB; 1DMP; X-ray; 2.00 A; A/B=489-587.
DR   PDB; 1DTQ; X-ray; 2.80 A; A=588-1147, B=588-1027.
DR   PDB; 1DTT; X-ray; 3.00 A; A=588-1147, B=588-1027.
DR   PDB; 1E6J; X-ray; 3.00 A; P=143-352.
DR   PDB; 1EP4; X-ray; 2.50 A; A=588-1147, B=588-1027.
DR   PDB; 1ESK; NMR; -; A=390-430.
DR   PDB; 1EX4; X-ray; 2.80 A; A/B=1199-1435.
DR   PDB; 1EXQ; X-ray; 1.60 A; A/B=1203-1356.
DR   PDB; 1FB7; X-ray; 2.60 A; A=489-587.
DR   PDB; 1FK9; X-ray; 2.50 A; A=588-1130, B=588-1027.
DR   PDB; 1FKO; X-ray; 2.90 A; A=588-1130, B=588-1027.
DR   PDB; 1FKP; X-ray; 2.90 A; A=588-1130, B=588-1027.
DR   PDB; 1G6L; X-ray; 1.90 A; A=484-587.
DR   PDB; 1HIV; X-ray; 2.00 A; A/B=489-587.
DR   PDB; 1HVH; X-ray; 1.80 A; A/B=489-587.
DR   PDB; 1HVR; X-ray; 1.80 A; A/B=489-587.
DR   PDB; 1HWR; X-ray; 1.80 A; A/B=489-587.
DR   PDB; 1HXB; X-ray; 2.30 A; A/B=489-587.
DR   PDB; 1JKH; X-ray; 2.50 A; A=588-1147, B=588-1027.
DR   PDB; 1JLA; X-ray; 2.50 A; A=588-1147, B=588-1027.
DR   PDB; 1JLB; X-ray; 3.00 A; A=588-1147, B=588-1027.
DR   PDB; 1JLC; X-ray; 3.00 A; A=588-1147, B=588-1027.
DR   PDB; 1JLE; X-ray; 2.80 A; A=588-1147, B=588-1027.
DR   PDB; 1JLF; X-ray; 2.60 A; A=588-1147, B=588-1027.
DR   PDB; 1JLG; X-ray; 2.60 A; A=588-1147, B=588-1027.
DR   PDB; 1JLQ; X-ray; 3.00 A; A=588-1147, B=588-1027.
DR   PDB; 1KLM; X-ray; 2.65 A; A=588-1147, B=588-1027.
DR   PDB; 1LV1; X-ray; 2.10 A; A=484-587.
DR   PDB; 1LW0; X-ray; 2.80 A; A=588-1147, B=588-1027.
DR   PDB; 1LW2; X-ray; 3.00 A; A=588-1147, B=588-1027.
DR   PDB; 1LWC; X-ray; 2.62 A; A=588-1147, B=588-1027.
DR   PDB; 1LWE; X-ray; 2.81 A; A=588-1147, B=588-1027.
DR   PDB; 1LWF; X-ray; 2.80 A; A=588-1147, B=588-1027.
DR   PDB; 1NCP; NMR; -; N=390-406.
DR   PDB; 1O1W; NMR; -; A=1014-1147.
DR   PDB; 1ODW; X-ray; 2.10 A; A/B=489-587.
DR   PDB; 1ODY; X-ray; 2.00 A; A/B=489-587.
DR   PDB; 1QBR; X-ray; 1.80 A; A/B=489-587.
DR   PDB; 1QBS; X-ray; 1.80 A; A/B=489-587.
DR   PDB; 1QBT; X-ray; 2.10 A; A/B=489-587.
DR   PDB; 1QBU; X-ray; 1.80 A; A/B=489-587.
DR   PDB; 1REV; X-ray; 2.60 A; A=588-1147, B=588-1027.
DR   PDB; 1RT1; X-ray; 2.55 A; A=588-1147, B=588-1027.
DR   PDB; 1RT2; X-ray; 2.55 A; A=588-1147, B=588-1027.
DR   PDB; 1RT3; X-ray; 3.00 A; A=588-1147, B=588-1027.
DR   PDB; 1RT4; X-ray; 2.90 A; A=588-1147, B=588-1027.
DR   PDB; 1RT5; X-ray; 2.90 A; A=588-1147, B=588-1027.
DR   PDB; 1RT6; X-ray; 2.80 A; A=588-1147, B=588-1027.
DR   PDB; 1RT7; X-ray; 3.00 A; A=588-1147, B=588-1027.
DR   PDB; 1RTD; X-ray; 3.20 A; B/D=588-1027.
DR   PDB; 1RTH; X-ray; 2.20 A; A=588-1147, B=588-1027.
DR   PDB; 1RTI; X-ray; 3.00 A; A=588-1147, B=588-1027.
DR   PDB; 1RTJ; X-ray; 2.35 A; A=588-1147, B=588-1027.
DR   PDB; 1S1T; X-ray; 2.40 A; A=588-1147, B=588-1027.
DR   PDB; 1S1U; X-ray; 3.00 A; A=588-1147, B=588-1027.
DR   PDB; 1S1V; X-ray; 2.60 A; A=588-1147, B=588-1027.
DR   PDB; 1S1W; X-ray; 2.70 A; A=588-1147, B=588-1027.
DR   PDB; 1S1X; X-ray; 2.80 A; A=588-1147, B=588-1027.
DR   PDB; 1T05; X-ray; 3.00 A; B=588-1016.
DR   PDB; 1TAM; NMR; -; A=1-132.
DR   PDB; 1TKT; X-ray; 2.60 A; A=588-1147, B=588-1027.
DR   PDB; 1TKX; X-ray; 2.85 A; A=588-1147, B=588-1027.
DR   PDB; 1TKZ; X-ray; 2.81 A; A=588-1147, B=588-1027.
DR   PDB; 1TL1; X-ray; 2.90 A; A=588-1147, B=588-1027.
DR   PDB; 1TL3; X-ray; 2.80 A; A=588-1147, B=588-1027.
DR   PDB; 1VRT; X-ray; 2.20 A; A=588-1147, B=588-1027.
DR   PDB; 1VRU; X-ray; 2.40 A; A=588-1147, B=588-1027.
DR   PDB; 2HND; X-ray; 2.50 A; A=591-1124.
DR   PDB; 2HNY; X-ray; 2.50 A; A=591-1124.
DR   PDB; 2HNZ; X-ray; 3.00 A; A=591-1124, B=594-1015.
DR   PDB; 2KOD; NMR; -; A/B=276-363.
DR   PDB; 2NPH; X-ray; 1.65 A; A/B=489-587.
DR   PDB; 2OPP; X-ray; 2.55 A; A=591-1132, B=592-1018.
DR   PDB; 2OPQ; X-ray; 2.80 A; A=591-1124, B=592-1015.
DR   PDB; 2OPR; X-ray; 2.90 A; A=589-1135, B=593-1018.
DR   PDB; 2OPS; X-ray; 2.30 A; A=589-1130, B=593-1027.
DR   PDB; 2RF2; X-ray; 2.40 A; A=588-1147, B=588-1027.
DR   PDB; 2RKI; X-ray; 2.30 A; A=588-1147, B=588-1027.
DR   PDB; 2WHH; X-ray; 1.69 A; A=489-587.
DR   PDB; 2WOM; X-ray; 3.20 A; A=588-1147, B=588-1027.
DR   PDB; 2WON; X-ray; 2.80 A; A=588-1147, B=588-1027.
DR   PDB; 2YNF; X-ray; 2.36 A; A=588-1147, B=588-1015.
DR   PDB; 2YNG; X-ray; 2.12 A; A=588-1147, B=588-1015.
DR   PDB; 2YNH; X-ray; 2.90 A; A=588-1147, B=588-1015.
DR   PDB; 2YNI; X-ray; 2.49 A; A=588-1147, B=588-1015.
DR   PDB; 3AO2; X-ray; 1.80 A; A/B=1197-1359.
DR   PDB; 3C6T; X-ray; 2.70 A; A=588-1147, B=588-1027.
DR   PDB; 3C6U; X-ray; 2.70 A; A=588-1147, B=588-1027.
DR   PDB; 3DI6; X-ray; 2.65 A; A=588-1148, B=588-1027.
DR   PDB; 3DLE; X-ray; 2.50 A; A=588-1147, B=588-1027.
DR   PDB; 3DLG; X-ray; 2.20 A; A=588-1147, B=588-1027.
DR   PDB; 3DM2; X-ray; 3.10 A; A=588-1147, B=588-1027.
DR   PDB; 3DMJ; X-ray; 2.60 A; A=588-1147, B=588-1027.
DR   PDB; 3DOK; X-ray; 2.90 A; A=588-1147, B=588-1027.
DR   PDB; 3DOL; X-ray; 2.50 A; A=588-1147, B=588-1027.
DR   PDB; 3DOX; X-ray; 2.00 A; A=484-587.
DR   PDB; 3DRP; X-ray; 2.60 A; A=588-1147, B=588-1027.
DR   PDB; 3DRR; X-ray; 2.89 A; A=588-1147, B=588-1027.
DR   PDB; 3DRS; X-ray; 3.15 A; A=588-1147, B=588-1027.
DR   PDB; 3DYA; X-ray; 2.30 A; A=588-1148, B=588-1027.
DR   PDB; 3E01; X-ray; 2.95 A; A=588-1148, B=588-1027.
DR   PDB; 3FFI; X-ray; 2.60 A; A=588-1147, B=588-1027.
DR   PDB; 3I0R; X-ray; 2.98 A; A=588-1147, B=588-1027.
DR   PDB; 3I0S; X-ray; 2.70 A; A=588-1147, B=588-1027.
DR   PDB; 3KJV; X-ray; 3.10 A; A=588-1147, B=588-1027.
DR   PDB; 3KK1; X-ray; 2.70 A; A=588-1147, B=588-1027.
DR   PDB; 3KK2; X-ray; 2.90 A; A=588-1147, B=588-1027.
DR   PDB; 3KK3; X-ray; 2.90 A; A=588-1147, B=588-1027.
DR   PDB; 3KT2; X-ray; 1.65 A; A=484-587.
DR   PDB; 3KT5; X-ray; 1.80 A; A=484-587.
DR   PDB; 3LAK; X-ray; 2.30 A; A/B=588-1147.
DR   PDB; 3LAL; X-ray; 2.51 A; A/B=588-1147.
DR   PDB; 3LAM; X-ray; 2.76 A; A/B=588-1147.
DR   PDB; 3LAN; X-ray; 2.55 A; A/B=588-1147.
DR   PDB; 3LP0; X-ray; 2.79 A; A=588-1147, B=588-1027.
DR   PDB; 3LP1; X-ray; 2.23 A; A=588-1147, B=588-1027.
DR   PDB; 3LP2; X-ray; 2.80 A; A=588-1147, B=588-1027.
DR   PDB; 3M8P; X-ray; 2.67 A; A=588-1148, B=588-1027.
DR   PDB; 3M8Q; X-ray; 2.70 A; A=588-1148, B=588-1027.
DR   PDB; 3MEC; X-ray; 2.30 A; A=588-1147, B=588-1027.
DR   PDB; 3MED; X-ray; 2.50 A; A=588-1147, B=588-1027.
DR   PDB; 3MEE; X-ray; 2.40 A; A=588-1147, B=588-1027.
DR   PDB; 3MEG; X-ray; 2.80 A; A=588-1147, B=588-1027.
DR   PDB; 3N3I; X-ray; 2.50 A; A=484-587.
DR   PDB; 3NBP; X-ray; 2.95 A; A=588-1148, B=588-1027.
DR   PDB; 3PHV; X-ray; 2.70 A; A=489-587.
DR   PDB; 3QIN; X-ray; 1.70 A; A=1014-1103, A=1142-1148.
DR   PDB; 3QIO; X-ray; 1.40 A; A=1014-1148.
DR   PDB; 3QIP; X-ray; 2.09 A; A=588-1147, B=588-1027.
DR   PDB; 3T19; X-ray; 2.60 A; A/B=588-1147.
DR   PDB; 3T1A; X-ray; 2.40 A; A/B=588-1147.
DR   PDB; 3TAM; X-ray; 2.51 A; A=590-1147, B=588-1027.
DR   PDB; 4B3O; X-ray; 3.30 A; A=588-1145, B=588-1027.
DR   PDB; 4B3P; X-ray; 4.84 A; A=588-1145, B=588-1027.
DR   PDB; 4B3Q; X-ray; 5.00 A; A=588-1145, B=588-1027.
DR   PDB; 4I7F; X-ray; 2.50 A; A=588-1147, B=588-1027.
DR   PDB; 4KSE; X-ray; 2.68 A; B=588-1017.
DR   PDB; 4KV8; X-ray; 2.30 A; A=588-1147, B=588-1027.
DR   PDB; 4NCG; X-ray; 2.58 A; A=588-1147, B=585-1027.
DR   PDB; 4Q1W; X-ray; 1.85 A; A/B=496-587.
DR   PDB; 4Q1X; X-ray; 1.90 A; A/B=496-587.
DR   PDB; 4Q1Y; X-ray; 1.50 A; A/B=496-587.
DR   PDB; 4Q5M; X-ray; 1.79 A; A=484-587.
DR   PDB; 4QLH; X-ray; 2.45 A; A=489-592.
DR   PDB; 4U1H; X-ray; 1.59 A; C=180-188.
DR   PDB; 4U1I; X-ray; 1.92 A; C=180-188.
DR   PDB; 4U1J; X-ray; 1.38 A; C=180-188.
DR   PDB; 4U7Q; X-ray; 1.70 A; A/B=496-587.
DR   PDB; 4U7V; X-ray; 1.38 A; A/B=496-587.
DR   PDB; 5DGU; X-ray; 1.22 A; A/B=496-587.
DR   PDB; 5DGW; X-ray; 1.62 A; A/B=496-587.
DR   PDB; 5EU7; X-ray; 2.64 A; A/B=1204-1356.
DR   PDB; 5HRN; X-ray; 1.75 A; A=1197-1359.
DR   PDB; 5HRP; X-ray; 1.81 A; A=1197-1359.
DR   PDB; 5HRR; X-ray; 1.88 A; A=1197-1359.
DR   PDB; 5HRS; X-ray; 1.86 A; A=1197-1359.
DR   PDB; 5IM7; X-ray; 2.50 A; E/F=308-316.
DR   PDB; 5J2M; X-ray; 2.43 A; A=588-1147, B=588-1027.
DR   PDB; 5J2N; X-ray; 2.90 A; A=588-1147, B=588-1027.
DR   PDB; 5J2P; X-ray; 2.53 A; A=588-1147, B=588-1027.
DR   PDB; 5J2Q; X-ray; 2.79 A; A=588-1147, B=588-1027.
DR   PDB; 5K14; X-ray; 2.40 A; A=588-1147.
DR   PDB; 5KAO; X-ray; 1.80 A; A/B=489-587.
DR   PDB; 5T82; NMR; -; A=824-905.
DR   PDB; 5TC2; X-ray; 1.84 A; A/B=1366-1420.
DR   PDB; 5VZ6; X-ray; 2.60 A; A=585-1147, B=585-1027.
DR   PDB; 5XOS; X-ray; 1.70 A; C=880-888.
DR   PDB; 5XOT; X-ray; 2.79 A; C=880-888.
DR   PDB; 5YRS; X-ray; 1.76 A; A/B=489-587.
DR   PDB; 6BJ2; X-ray; 3.35 A; C=880-888.
DR   PDB; 6BJ3; X-ray; 1.90 A; C=880-888.
DR   PDB; 6BSG; X-ray; 2.44 A; A=588-1144, B=588-1027.
DR   PDB; 6BSH; X-ray; 2.65 A; A=588-1144, B=588-1027.
DR   PDB; 6BSI; X-ray; 3.25 A; A=588-1144, B=588-1027.
DR   PDB; 6BSJ; X-ray; 2.89 A; A=588-1144, B=588-1027.
DR   PDB; 6DIF; X-ray; 1.20 A; A/B=489-587.
DR   PDB; 6DIL; X-ray; 1.48 A; A/B=489-587.
DR   PDB; 6DJ1; X-ray; 1.26 A; A/B=489-587.
DR   PDB; 6DJ2; X-ray; 1.36 A; A/B=489-587.
DR   PDB; 6DJ5; X-ray; 1.75 A; A/B=489-587.
DR   PDB; 6DJ7; X-ray; 1.31 A; A/B=489-587.
DR   PDB; 6DV0; X-ray; 1.20 A; A/B=489-587.
DR   PDB; 6DV4; X-ray; 1.14 A; A/B=489-587.
DR   PDB; 6E7J; X-ray; 1.30 A; A/B=489-587.
DR   PDB; 6E9A; X-ray; 1.22 A; A/B=489-587.
DR   PDB; 6EWA; X-ray; 2.39 A; C/G=896-904.
DR   PDB; 6EX9; X-ray; 2.01 A; A=1204-1355.
DR   PDB; 6GL1; X-ray; 2.62 A; P/Q/R/T=275-283.
DR   PDB; 6J1V; X-ray; 2.00 A; C=745-753.
DR   PDB; 6J1W; X-ray; 1.50 A; C=745-753.
DR   PDB; 6OR7; X-ray; 2.53 A; A=588-1147, B=588-1027.
DR   PDB; 6OTZ; X-ray; 2.86 A; A=588-1145, B=588-1027.
DR   PDB; 6P1I; X-ray; 2.74 A; A=588-1147, B=588-1027.
DR   PDB; 6P1X; X-ray; 2.55 A; A=588-1147, B=588-1027.
DR   PDB; 6P2G; X-ray; 2.99 A; A=588-1147, B=588-1027.
DR   PDB; 6PYL; X-ray; 1.52 A; C=263-272.
DR   PDB; 6SKK; EM; 3.60 A; A/B/C/D/E/F=133-363.
DR   PDB; 6SKM; EM; 4.90 A; A/B/C/D/E/F=133-363.
DR   PDB; 6SKN; EM; 4.50 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R=133-363.
DR   PDB; 6SLQ; EM; 4.40 A; A/B/C/D/E/F=133-363.
DR   PDB; 6SLU; EM; 4.70 A; A/B/C/D/E/F=133-363.
DR   PDB; 6SMU; EM; 5.00 A; A/B/C/D/E/F=133-363.
DR   PDB; 6UIR; X-ray; 2.64 A; A=588-1147, B=588-1027.
DR   PDB; 6UIS; X-ray; 2.75 A; A=588-1147, B=588-1027.
DR   PDB; 6UIT; X-ray; 2.81 A; A=588-1147, B=588-1027.
DR   PDB; 6UJX; X-ray; 2.70 A; A=588-1147, B=588-1027.
DR   PDB; 6UJY; X-ray; 2.59 A; A=588-1147, B=588-1027.
DR   PDB; 6UJZ; X-ray; 2.56 A; A=588-1147, B=588-1027.
DR   PDB; 6UK0; X-ray; 2.76 A; A=588-1147, B=588-1027.
DR   PDB; 6VPZ; X-ray; 2.10 A; C=263-273.
DR   PDB; 6VQ2; X-ray; 2.25 A; C=263-276.
DR   PDB; 6VQD; X-ray; 1.88 A; C=263-270.
DR   PDB; 6VQE; X-ray; 1.77 A; C=263-275.
DR   PDB; 6VQY; X-ray; 2.57 A; F/G=263-269.
DR   PDB; 6VQZ; X-ray; 2.25 A; F/G=263-268.
DR   PDB; 6WAZ; EM; 4.10 A; B=588-1027.
DR   PDB; 6WB1; EM; 4.70 A; B=588-1027.
DR   PDB; 6WPF; X-ray; 2.53 A; A=588-1147, B=588-1027.
DR   PDB; 6WPH; X-ray; 2.72 A; A=588-1147, B=588-1027.
DR   PDB; 6WPJ; X-ray; 2.73 A; A=588-1147, B=588-1027.
DR   PDB; 7DOZ; X-ray; 1.91 A; A=489-593.
DR   PDB; 7DPQ; X-ray; 1.65 A; A=489-593.
DR   PDB; 7DT9; X-ray; 1.89 A; A=489-593.
DR   PDB; 7R7V; X-ray; 1.60 A; C=308-316.
DR   PDB; 7R7X; X-ray; 2.10 A; E/F=308-316.
DR   PDB; 7R80; X-ray; 2.90 A; E=308-316.
DR   PDB; 7SLR; X-ray; 2.18 A; A/B=587-1147.
DR   PDB; 7SLS; X-ray; 2.08 A; A/B=587-1147.
DR   PDB; 7XIS; X-ray; 1.88 A; A=1014-1093, A=1103-1148.
DR   PDB; 7XIT; X-ray; 2.18 A; A=1014-1093, A=1103-1148.
DR   PDB; 7XIU; X-ray; 2.09 A; A=1014-1087, A=1103-1148.
DR   PDB; 7XJ4; X-ray; 1.80 A; A=1014-1087, A=1103-1148.
DR   PDB; 7XJ5; X-ray; 1.75 A; A=1014-1087, A=1103-1148.
DR   PDB; 7XJ7; X-ray; 1.80 A; A=1014-1087, A=1103-1148.
DR   PDB; 8ERX; X-ray; 2.07 A; C=745-753.
DR   PDB; 8ESX; X-ray; 1.35 A; A/B=489-587.
DR   PDB; 8ESY; X-ray; 1.35 A; A/B=489-587.
DR   PDB; 8F0F; X-ray; 1.29 A; A/B=489-587.
DR   PDB; 8F5A; X-ray; 1.95 A; E=240-249.
DR   PDB; 8F7M; X-ray; 1.88 A; C=240-249.
DR   PDB; 8FCC; X-ray; 2.57 A; A=588-1147, B=588-1027.
DR   PDB; 8FCD; X-ray; 2.57 A; A=588-1147, B=588-1027.
DR   PDB; 8FCE; X-ray; 2.77 A; A=588-1147, B=588-1027.
DR   PDB; 8JYH; X-ray; 2.21 A; A=1014-1148.
DR   PDB; 8JYI; X-ray; 1.92 A; A=1014-1148.
DR   PDB; 8JYJ; X-ray; 2.01 A; A=1014-1148.
DR   PDB; 8TCJ; X-ray; 1.85 A; B=588-1005.
DR   PDB; 8TCK; X-ray; 2.20 A; B=588-1005.
DR   PDB; 8TCL; X-ray; 1.95 A; B=588-1005.
DR   PDB; 8TCM; X-ray; 1.82 A; B=588-1005.
DR   PDBsum; 1A30; -.
DR   PDBsum; 1BV7; -.
DR   PDBsum; 1BV9; -.
DR   PDBsum; 1BVE; -.
DR   PDBsum; 1BVG; -.
DR   PDBsum; 1BWA; -.
DR   PDBsum; 1BWB; -.
DR   PDBsum; 1C0T; -.
DR   PDBsum; 1C0U; -.
DR   PDBsum; 1C1B; -.
DR   PDBsum; 1C1C; -.
DR   PDBsum; 1DMP; -.
DR   PDBsum; 1DTQ; -.
DR   PDBsum; 1DTT; -.
DR   PDBsum; 1E6J; -.
DR   PDBsum; 1EP4; -.
DR   PDBsum; 1ESK; -.
DR   PDBsum; 1EX4; -.
DR   PDBsum; 1EXQ; -.
DR   PDBsum; 1FB7; -.
DR   PDBsum; 1FK9; -.
DR   PDBsum; 1FKO; -.
DR   PDBsum; 1FKP; -.
DR   PDBsum; 1G6L; -.
DR   PDBsum; 1HIV; -.
DR   PDBsum; 1HVH; -.
DR   PDBsum; 1HVR; -.
DR   PDBsum; 1HWR; -.
DR   PDBsum; 1HXB; -.
DR   PDBsum; 1JKH; -.
DR   PDBsum; 1JLA; -.
DR   PDBsum; 1JLB; -.
DR   PDBsum; 1JLC; -.
DR   PDBsum; 1JLE; -.
DR   PDBsum; 1JLF; -.
DR   PDBsum; 1JLG; -.
DR   PDBsum; 1JLQ; -.
DR   PDBsum; 1KLM; -.
DR   PDBsum; 1LV1; -.
DR   PDBsum; 1LW0; -.
DR   PDBsum; 1LW2; -.
DR   PDBsum; 1LWC; -.
DR   PDBsum; 1LWE; -.
DR   PDBsum; 1LWF; -.
DR   PDBsum; 1NCP; -.
DR   PDBsum; 1O1W; -.
DR   PDBsum; 1ODW; -.
DR   PDBsum; 1ODY; -.
DR   PDBsum; 1QBR; -.
DR   PDBsum; 1QBS; -.
DR   PDBsum; 1QBT; -.
DR   PDBsum; 1QBU; -.
DR   PDBsum; 1REV; -.
DR   PDBsum; 1RT1; -.
DR   PDBsum; 1RT2; -.
DR   PDBsum; 1RT3; -.
DR   PDBsum; 1RT4; -.
DR   PDBsum; 1RT5; -.
DR   PDBsum; 1RT6; -.
DR   PDBsum; 1RT7; -.
DR   PDBsum; 1RTD; -.
DR   PDBsum; 1RTH; -.
DR   PDBsum; 1RTI; -.
DR   PDBsum; 1RTJ; -.
DR   PDBsum; 1S1T; -.
DR   PDBsum; 1S1U; -.
DR   PDBsum; 1S1V; -.
DR   PDBsum; 1S1W; -.
DR   PDBsum; 1S1X; -.
DR   PDBsum; 1T05; -.
DR   PDBsum; 1TAM; -.
DR   PDBsum; 1TKT; -.
DR   PDBsum; 1TKX; -.
DR   PDBsum; 1TKZ; -.
DR   PDBsum; 1TL1; -.
DR   PDBsum; 1TL3; -.
DR   PDBsum; 1VRT; -.
DR   PDBsum; 1VRU; -.
DR   PDBsum; 2HND; -.
DR   PDBsum; 2HNY; -.
DR   PDBsum; 2HNZ; -.
DR   PDBsum; 2KOD; -.
DR   PDBsum; 2NPH; -.
DR   PDBsum; 2OPP; -.
DR   PDBsum; 2OPQ; -.
DR   PDBsum; 2OPR; -.
DR   PDBsum; 2OPS; -.
DR   PDBsum; 2RF2; -.
DR   PDBsum; 2RKI; -.
DR   PDBsum; 2WHH; -.
DR   PDBsum; 2WOM; -.
DR   PDBsum; 2WON; -.
DR   PDBsum; 2YNF; -.
DR   PDBsum; 2YNG; -.
DR   PDBsum; 2YNH; -.
DR   PDBsum; 2YNI; -.
DR   PDBsum; 3AO2; -.
DR   PDBsum; 3C6T; -.
DR   PDBsum; 3C6U; -.
DR   PDBsum; 3DI6; -.
DR   PDBsum; 3DLE; -.
DR   PDBsum; 3DLG; -.
DR   PDBsum; 3DM2; -.
DR   PDBsum; 3DMJ; -.
DR   PDBsum; 3DOK; -.
DR   PDBsum; 3DOL; -.
DR   PDBsum; 3DOX; -.
DR   PDBsum; 3DRP; -.
DR   PDBsum; 3DRR; -.
DR   PDBsum; 3DRS; -.
DR   PDBsum; 3DYA; -.
DR   PDBsum; 3E01; -.
DR   PDBsum; 3FFI; -.
DR   PDBsum; 3I0R; -.
DR   PDBsum; 3I0S; -.
DR   PDBsum; 3KJV; -.
DR   PDBsum; 3KK1; -.
DR   PDBsum; 3KK2; -.
DR   PDBsum; 3KK3; -.
DR   PDBsum; 3KT2; -.
DR   PDBsum; 3KT5; -.
DR   PDBsum; 3LAK; -.
DR   PDBsum; 3LAL; -.
DR   PDBsum; 3LAM; -.
DR   PDBsum; 3LAN; -.
DR   PDBsum; 3LP0; -.
DR   PDBsum; 3LP1; -.
DR   PDBsum; 3LP2; -.
DR   PDBsum; 3M8P; -.
DR   PDBsum; 3M8Q; -.
DR   PDBsum; 3MEC; -.
DR   PDBsum; 3MED; -.
DR   PDBsum; 3MEE; -.
DR   PDBsum; 3MEG; -.
DR   PDBsum; 3N3I; -.
DR   PDBsum; 3NBP; -.
DR   PDBsum; 3PHV; -.
DR   PDBsum; 3QIN; -.
DR   PDBsum; 3QIO; -.
DR   PDBsum; 3QIP; -.
DR   PDBsum; 3T19; -.
DR   PDBsum; 3T1A; -.
DR   PDBsum; 3TAM; -.
DR   PDBsum; 4B3O; -.
DR   PDBsum; 4B3P; -.
DR   PDBsum; 4B3Q; -.
DR   PDBsum; 4I7F; -.
DR   PDBsum; 4KSE; -.
DR   PDBsum; 4KV8; -.
DR   PDBsum; 4NCG; -.
DR   PDBsum; 4Q1W; -.
DR   PDBsum; 4Q1X; -.
DR   PDBsum; 4Q1Y; -.
DR   PDBsum; 4Q5M; -.
DR   PDBsum; 4QLH; -.
DR   PDBsum; 4U1H; -.
DR   PDBsum; 4U1I; -.
DR   PDBsum; 4U1J; -.
DR   PDBsum; 4U7Q; -.
DR   PDBsum; 4U7V; -.
DR   PDBsum; 5DGU; -.
DR   PDBsum; 5DGW; -.
DR   PDBsum; 5EU7; -.
DR   PDBsum; 5HRN; -.
DR   PDBsum; 5HRP; -.
DR   PDBsum; 5HRR; -.
DR   PDBsum; 5HRS; -.
DR   PDBsum; 5IM7; -.
DR   PDBsum; 5J2M; -.
DR   PDBsum; 5J2N; -.
DR   PDBsum; 5J2P; -.
DR   PDBsum; 5J2Q; -.
DR   PDBsum; 5K14; -.
DR   PDBsum; 5KAO; -.
DR   PDBsum; 5T82; -.
DR   PDBsum; 5TC2; -.
DR   PDBsum; 5VZ6; -.
DR   PDBsum; 5XOS; -.
DR   PDBsum; 5XOT; -.
DR   PDBsum; 5YRS; -.
DR   PDBsum; 6BJ2; -.
DR   PDBsum; 6BJ3; -.
DR   PDBsum; 6BSG; -.
DR   PDBsum; 6BSH; -.
DR   PDBsum; 6BSI; -.
DR   PDBsum; 6BSJ; -.
DR   PDBsum; 6DIF; -.
DR   PDBsum; 6DIL; -.
DR   PDBsum; 6DJ1; -.
DR   PDBsum; 6DJ2; -.
DR   PDBsum; 6DJ5; -.
DR   PDBsum; 6DJ7; -.
DR   PDBsum; 6DV0; -.
DR   PDBsum; 6DV4; -.
DR   PDBsum; 6E7J; -.
DR   PDBsum; 6E9A; -.
DR   PDBsum; 6EWA; -.
DR   PDBsum; 6EX9; -.
DR   PDBsum; 6GL1; -.
DR   PDBsum; 6J1V; -.
DR   PDBsum; 6J1W; -.
DR   PDBsum; 6OR7; -.
DR   PDBsum; 6OTZ; -.
DR   PDBsum; 6P1I; -.
DR   PDBsum; 6P1X; -.
DR   PDBsum; 6P2G; -.
DR   PDBsum; 6PYL; -.
DR   PDBsum; 6SKK; -.
DR   PDBsum; 6SKM; -.
DR   PDBsum; 6SKN; -.
DR   PDBsum; 6SLQ; -.
DR   PDBsum; 6SLU; -.
DR   PDBsum; 6SMU; -.
DR   PDBsum; 6UIR; -.
DR   PDBsum; 6UIS; -.
DR   PDBsum; 6UIT; -.
DR   PDBsum; 6UJX; -.
DR   PDBsum; 6UJY; -.
DR   PDBsum; 6UJZ; -.
DR   PDBsum; 6UK0; -.
DR   PDBsum; 6VPZ; -.
DR   PDBsum; 6VQ2; -.
DR   PDBsum; 6VQD; -.
DR   PDBsum; 6VQE; -.
DR   PDBsum; 6VQY; -.
DR   PDBsum; 6VQZ; -.
DR   PDBsum; 6WAZ; -.
DR   PDBsum; 6WB1; -.
DR   PDBsum; 6WPF; -.
DR   PDBsum; 6WPH; -.
DR   PDBsum; 6WPJ; -.
DR   PDBsum; 7DOZ; -.
DR   PDBsum; 7DPQ; -.
DR   PDBsum; 7DT9; -.
DR   PDBsum; 7R7V; -.
DR   PDBsum; 7R7X; -.
DR   PDBsum; 7R80; -.
DR   PDBsum; 7SLR; -.
DR   PDBsum; 7SLS; -.
DR   PDBsum; 7XIS; -.
DR   PDBsum; 7XIT; -.
DR   PDBsum; 7XIU; -.
DR   PDBsum; 7XJ4; -.
DR   PDBsum; 7XJ5; -.
DR   PDBsum; 7XJ7; -.
DR   PDBsum; 8ERX; -.
DR   PDBsum; 8ESX; -.
DR   PDBsum; 8ESY; -.
DR   PDBsum; 8F0F; -.
DR   PDBsum; 8F5A; -.
DR   PDBsum; 8F7M; -.
DR   PDBsum; 8FCC; -.
DR   PDBsum; 8FCD; -.
DR   PDBsum; 8FCE; -.
DR   PDBsum; 8JYH; -.
DR   PDBsum; 8JYI; -.
DR   PDBsum; 8JYJ; -.
DR   PDBsum; 8TCJ; -.
DR   PDBsum; 8TCK; -.
DR   PDBsum; 8TCL; -.
DR   PDBsum; 8TCM; -.
DR   BMRB; P04585; -.
DR   SASBDB; P04585; -.
DR   SMR; P04585; -.
DR   BioGRID; 1205538; 133.
DR   IntAct; P04585; 7.
DR   MINT; P04585; -.
DR   BindingDB; P04585; -.
DR   ChEMBL; CHEMBL3638360; -.
DR   DrugBank; DB07910; (2S)-2-amino-3-phenylpropane-1,1-diol.
DR   DrugBank; DB07473; (R)-(+) 5(9BH)-OXO-9B-PHENYL-2,3-DIHYDROTHIAZOLO[2,3-A]ISOINDOL-3-CARBOXYLIC ACID METHYL ESTER.
DR   DrugBank; DB07472; (R)-(+)9B-(3-METHYL)PHENYL-2,3-DIHYDROTHIAZOLO[2,3-A]ISOINDOL-5(9BH)-ONE.
DR   DrugBank; DB07892; 1-(2-HYDROXYETHYLOXYMETHYL)-6-PHENYL THIOTHYMINE.
DR   DrugBank; DB08372; 1-[2-(4-ETHOXY-3-FLUOROPYRIDIN-2-YL)ETHYL]-3-(5-METHYLPYRIDIN-2-YL)THIOUREA.
DR   DrugBank; DB08682; 1-METHYL ETHYL 1-CHLORO-5-[[(5,6DIHYDRO-2-METHYL-1,4-OXATHIIN-3-YL)CARBONYL]AMINO]BENZOATE.
DR   DrugBank; DB08681; 1-METHYL ETHYL 2-CHLORO-5-[[[(1-METHYLETHOXY)THIOOXO]METHYL]AMINO]-BENZOATE.
DR   DrugBank; DB08286; 1-Naphthoxyacetic acid.
DR   DrugBank; DB07826; 2-[4-chloro-2-(phenylcarbonyl)phenoxy]-N-phenylacetamide.
DR   DrugBank; DB08528; 2-AMINO-6-(3,5-DIMETHYLPHENYL)SULFONYLBENZONITRILE.
DR   DrugBank; DB08444; 3-[2-bromo-4-(1H-pyrazolo[3,4-c]pyridazin-3-ylmethyl)phenoxy]-5-methylbenzonitrile.
DR   DrugBank; DB08446; 3-[6-bromo-2-fluoro-3-(1H-pyrazolo[3,4-c]pyridazin-3-ylmethyl)phenoxy]-5-chlorobenzonitrile.
DR   DrugBank; DB08154; 3-chloro-5-[2-chloro-5-(1H-indazol-3-ylmethoxy)phenoxy]benzonitrile.
DR   DrugBank; DB08459; 3-chloro-5-[2-chloro-5-(1H-pyrazolo[3,4-b]pyridin-3-ylmethoxy)phenoxy]benzonitrile.
DR   DrugBank; DB07864; 4-[(CYCLOPROPYLETHYNYL)OXY]-6-FLUORO-3-ISOPROPYLQUINOLIN-2(1H)-ONE.
DR   DrugBank; DB08211; 5-bromo-3-(pyrrolidin-1-ylsulfonyl)-1H-indole-2-carboxamide.
DR   DrugBank; DB08665; 6,11-DIHYDRO-11-ETHYL-6-METHYL-9-NITRO-5H-PYRIDO[2,3-B][1,5]BENZODIAZEPIN-5-ONE.
DR   DrugBank; DB07820; 6-(3',5'-DIMETHYLBENZYL)-1-ETHOXYMETHYL-5-ISOPROPYLURACIL.
DR   DrugBank; DB08379; 6-(4-chloro-2-fluoro-3-phenoxybenzyl)pyridazin-3(2H)-one.
DR   DrugBank; DB07184; 6-(cyclohexylsulfanyl)-1-(ethoxymethyl)-5-(1-methylethyl)pyrimidine-2,4(1H,3H)-dione.
DR   DrugBank; DB08634; 6-BENZYL-1-BENZYLOXYMETHYL-5-ISOPROPYL URACIL.
DR   DrugBank; DB07871; 6-CHLORO-4-(CYCLOHEXYLOXY)-3-ISOPROPYLQUINOLIN-2(1H)-ONE.
DR   DrugBank; DB07867; 6-CHLORO-4-(CYCLOHEXYLOXY)-3-PROPYLQUINOLIN-2(1H)-ONE.
DR   DrugBank; DB07868; 6-CHLORO-4-(CYCLOHEXYLSULFANYL)-3-PROPYLQUINOLIN-2(1H)-ONE.
DR   DrugBank; DB07869; 6-Chloro-4-[(R)-cyclohexylsulfinyl]-3-propyl-2(1H)-quinolinone.
DR   DrugBank; DB06910; [4-R-(4-ALPHA,6-BETA,7-BETA]-HEXAHYDRO-5,6-DI(HYDROXY)-1,3-DI(ALLYL)-4,7-BISPHENYLMETHYL)-2H-1,3-DIAZEPINONE.
DR   DrugBank; DB07332; ALPHA-(2,6-DICHLOROPHENYL)-ALPHA-(2-ACETYL-5-METHYLANILINO)ACETAMIDE.
DR   DrugBank; DB06581; Bevirimat.
DR   DrugBank; DB08502; Capravirine.
DR   DrugBank; DB08188; Emivirine.
DR   DrugBank; DB06414; Etravirine.
DR   DrugBank; DB13119; GSK-364735.
DR   DrugBank; DB04609; INHIBITOR Q8467 OF DUPONT MERCK.
DR   DrugBank; DB15673; Lenacapavir.
DR   DrugBank; DB08460; MK-4965.
DR   DrugBank; DB02102; Mozenavir.
DR   DrugBank; DB07797; N-[[3-FLUORO-4-ETHOXY-PYRID-2-YL]ETHYL]-N'-[5-CHLORO-PYRIDYL]-THIOUREA.
DR   DrugBank; DB07781; N-[[3-FLUORO-4-ETHOXY-PYRID-2-YL]ETHYL]-N'-[5-NITRILOMETHYL-PYRIDYL]-THIOUREA.
DR   DrugBank; DB08680; N-{3-[(E)-(tert-butoxyimino)methyl]-4-chlorophenyl}-2-methylfuran-3-carbimidothioic acid.
DR   DrugBank; DB07884; Opaviraline.
DR   DrugBank; DB08598; R-82913.
DR   DrugBank; DB08494; S-{2-[(2-chloro-4-sulfamoylphenyl)amino]-2-oxoethyl} 6-methyl-3,4-dihydroquinoline-1(2H)-carbothioate.
DR   DrugBank; DB02729; SD146.
DR   DrugBank; DB05328; VGV-1.
DR   DrugBank; DB02702; XV638.
DR   MEROPS; A02.001; -.
DR   ABCD; P04585; 3 sequenced antibodies.
DR   GeneID; 155348; -.
DR   KEGG; vg:155348; -.
DR   Reactome; R-HSA-162585; Uncoating of the HIV Virion.
DR   Reactome; R-HSA-162588; Budding and maturation of HIV virion.
DR   Reactome; R-HSA-162592; Integration of provirus.
DR   Reactome; R-HSA-162594; Early Phase of HIV Life Cycle.
DR   Reactome; R-HSA-164516; Minus-strand DNA synthesis.
DR   Reactome; R-HSA-164525; Plus-strand DNA synthesis.
DR   Reactome; R-HSA-164843; 2-LTR circle formation.
DR   Reactome; R-HSA-173107; Binding and entry of HIV virion.
DR   Reactome; R-HSA-175474; Assembly Of The HIV Virion.
DR   Reactome; R-HSA-175567; Integration of viral DNA into host genomic DNA.
DR   Reactome; R-HSA-177539; Autointegration results in viral DNA circles.
DR   Reactome; R-HSA-180689; APOBEC3G mediated resistance to HIV-1 infection.
DR   Reactome; R-HSA-180910; Vpr-mediated nuclear import of PICs.
DR   SABIO-RK; P04585; -.
DR   EvolutionaryTrace; P04585; -.
DR   PRO; PR:P04585; -.
DR   Proteomes; UP000002241; Segment.
DR   Proteomes; UP000105453; Segment.
DR   GO; GO:0043657; C:host cell; IEA:GOC.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0072494; C:host multivesicular body; IEA:UniProtKB-SubCell.
DR   GO; GO:0019013; C:viral nucleocapsid; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004190; F:aspartic-type endopeptidase activity; IDA:UniProt.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003887; F:DNA-directed DNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004533; F:exoribonuclease H activity; IEA:UniProtKB-EC.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0008907; F:integrase activity; TAS:Reactome.
DR   GO; GO:0008289; F:lipid binding; IEA:UniProtKB-KW.
DR   GO; GO:0008233; F:peptidase activity; TAS:Reactome.
DR   GO; GO:0035613; F:RNA stem-loop binding; IEA:TreeGrafter.
DR   GO; GO:0003964; F:RNA-directed DNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004523; F:RNA-DNA hybrid ribonuclease activity; IEA:InterPro.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IDA:CAFA.
DR   GO; GO:0006310; P:DNA recombination; IEA:UniProtKB-KW.
DR   GO; GO:0075713; P:establishment of integrated proviral latency; TAS:Reactome.
DR   GO; GO:0016485; P:protein processing; IDA:UniProt.
DR   GO; GO:0046718; P:symbiont entry into host cell; IEA:UniProtKB-KW.
DR   GO; GO:0052151; P:symbiont-mediated activation of host apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0039657; P:symbiont-mediated suppression of host gene expression; IEA:UniProtKB-KW.
DR   GO; GO:0044826; P:viral genome integration into host DNA; IEA:UniProtKB-KW.
DR   GO; GO:0019058; P:viral life cycle; TAS:Reactome.
DR   GO; GO:0075732; P:viral penetration into host nucleus; IEA:UniProtKB-KW.
DR   GO; GO:0075523; P:viral translational frameshifting; IEA:UniProtKB-KW.
DR   CDD; cd05482; HIV_retropepsin_like; 1.
DR   CDD; cd01645; RT_Rtv; 1.
DR   FunFam; 1.10.1200.30:FF:000001; Gag polyprotein; 1.
DR   FunFam; 1.10.150.90:FF:000001; Gag polyprotein; 1.
DR   FunFam; 1.10.375.10:FF:000001; Gag polyprotein; 1.
DR   FunFam; 1.20.5.760:FF:000001; Gag polyprotein; 1.
DR   FunFam; 4.10.60.10:FF:000001; Gag polyprotein; 1.
DR   FunFam; 2.40.70.10:FF:000001; Gag-Pol polyprotein; 1.
DR   FunFam; 3.30.420.10:FF:000025; Gag-Pol polyprotein; 1.
DR   FunFam; 2.30.30.10:FF:000001; POL polyprotein; 1.
DR   FunFam; 3.30.420.10:FF:000017; POL polyprotein; 1.
DR   FunFam; 3.30.70.270:FF:000016; POL polyprotein; 1.
DR   Gene3D; 1.10.10.200; -; 1.
DR   Gene3D; 1.10.1200.30; -; 1.
DR   Gene3D; 3.30.70.270; -; 3.
DR   Gene3D; 2.40.70.10; Acid Proteases; 1.
DR   Gene3D; 3.10.10.10; HIV Type 1 Reverse Transcriptase, subunit A, domain 1; 1.
DR   Gene3D; 1.10.375.10; Human Immunodeficiency Virus Type 1 Capsid Protein; 1.
DR   Gene3D; 1.10.150.90; Immunodeficiency lentiviruses, gag gene matrix protein p17; 1.
DR   Gene3D; 2.30.30.10; Integrase, C-terminal domain superfamily, retroviral; 1.
DR   Gene3D; 3.30.420.10; Ribonuclease H-like superfamily/Ribonuclease H; 2.
DR   Gene3D; 1.20.5.760; Single helix bin; 1.
DR   Gene3D; 4.10.60.10; Zinc finger, CCHC-type; 1.
DR   InterPro; IPR001969; Aspartic_peptidase_AS.
DR   InterPro; IPR043502; DNA/RNA_pol_sf.
DR   InterPro; IPR045345; Gag_p24_C.
DR   InterPro; IPR017856; Integrase-like_N.
DR   InterPro; IPR036862; Integrase_C_dom_sf_retrovir.
DR   InterPro; IPR001037; Integrase_C_retrovir.
DR   InterPro; IPR001584; Integrase_cat-core.
DR   InterPro; IPR003308; Integrase_Zn-bd_dom_N.
DR   InterPro; IPR000071; Lentvrl_matrix_N.
DR   InterPro; IPR012344; Matrix_HIV/RSV_N.
DR   InterPro; IPR001995; Peptidase_A2_cat.
DR   InterPro; IPR021109; Peptidase_aspartic_dom_sf.
DR   InterPro; IPR034170; Retropepsin-like_cat_dom.
DR   InterPro; IPR018061; Retropepsins.
DR   InterPro; IPR008916; Retrov_capsid_C.
DR   InterPro; IPR008919; Retrov_capsid_N.
DR   InterPro; IPR010999; Retrovr_matrix.
DR   InterPro; IPR043128; Rev_trsase/Diguanyl_cyclase.
DR   InterPro; IPR012337; RNaseH-like_sf.
DR   InterPro; IPR002156; RNaseH_domain.
DR   InterPro; IPR036397; RNaseH_sf.
DR   InterPro; IPR000477; RT_dom.
DR   InterPro; IPR010659; RVT_connect.
DR   InterPro; IPR010661; RVT_thumb.
DR   InterPro; IPR001878; Znf_CCHC.
DR   InterPro; IPR036875; Znf_CCHC_sf.
DR   PANTHER; PTHR41694; ENDOGENOUS RETROVIRUS GROUP K MEMBER POL PROTEIN; 1.
DR   PANTHER; PTHR41694:SF3; RNA-DIRECTED DNA POLYMERASE-RELATED; 1.
DR   Pfam; PF00540; Gag_p17; 1.
DR   Pfam; PF19317; Gag_p24_C; 1.
DR   Pfam; PF00552; IN_DBD_C; 1.
DR   Pfam; PF02022; Integrase_Zn; 1.
DR   Pfam; PF00075; RNase_H; 1.
DR   Pfam; PF00665; rve; 1.
DR   Pfam; PF00077; RVP; 1.
DR   Pfam; PF00078; RVT_1; 1.
DR   Pfam; PF06815; RVT_connect; 1.
DR   Pfam; PF06817; RVT_thumb; 1.
DR   Pfam; PF00098; zf-CCHC; 2.
DR   PRINTS; PR00234; HIV1MATRIX.
DR   SMART; SM00343; ZnF_C2HC; 2.
DR   SUPFAM; SSF50630; Acid proteases; 1.
DR   SUPFAM; SSF50122; DNA-binding domain of retroviral integrase; 1.
DR   SUPFAM; SSF56672; DNA/RNA polymerases; 1.
DR   SUPFAM; SSF46919; N-terminal Zn binding domain of HIV integrase; 1.
DR   SUPFAM; SSF47836; Retroviral matrix proteins; 1.
DR   SUPFAM; SSF47353; Retrovirus capsid dimerization domain-like; 1.
DR   SUPFAM; SSF47943; Retrovirus capsid protein, N-terminal core domain; 1.
DR   SUPFAM; SSF57756; Retrovirus zinc finger-like domains; 1.
DR   SUPFAM; SSF53098; Ribonuclease H-like; 2.
DR   PROSITE; PS50175; ASP_PROT_RETROV; 1.
DR   PROSITE; PS00141; ASP_PROTEASE; 1.
DR   PROSITE; PS50994; INTEGRASE; 1.
DR   PROSITE; PS51027; INTEGRASE_DBD; 1.
DR   PROSITE; PS50879; RNASE_H_1; 1.
DR   PROSITE; PS50878; RT_POL; 1.
DR   PROSITE; PS50158; ZF_CCHC; 2.
DR   PROSITE; PS50876; ZF_INTEGRASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activation of host caspases by virus; AIDS;
KW   Aspartyl protease; Capsid protein; DNA integration; DNA recombination;
KW   DNA-binding; DNA-directed DNA polymerase; Endonuclease;
KW   Eukaryotic host gene expression shutoff by virus;
KW   Eukaryotic host translation shutoff by virus; Host cell membrane;
KW   Host cytoplasm; Host endosome; Host gene expression shutoff by virus;
KW   Host membrane; Host nucleus; Host-virus interaction; Hydrolase;
KW   Lipid-binding; Lipoprotein; Magnesium; Membrane; Metal-binding;
KW   Modulation of host cell apoptosis by virus; Multifunctional enzyme;
KW   Myristate; Nuclease; Nucleotidyltransferase; Phosphoprotein; Protease;
KW   Reference proteome; Repeat; Ribosomal frameshifting; RNA-binding;
KW   RNA-directed DNA polymerase; Transferase; Viral genome integration;
KW   Viral nucleoprotein; Viral penetration into host nucleus;
KW   Viral release from host cell; Virion; Virion maturation;
KW   Virus entry into host cell; Zinc; Zinc-finger.
FT   INIT_MET        1
FT                   /note="Removed; by host"
FT                   /evidence="ECO:0000250"
FT   CHAIN           2..1435
FT                   /note="Gag-Pol polyprotein"
FT                   /id="PRO_0000223620"
FT   CHAIN           2..132
FT                   /note="Matrix protein p17"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000042439"
FT   CHAIN           133..363
FT                   /note="Capsid protein p24"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000042440"
FT   PEPTIDE         364..377
FT                   /note="Spacer peptide 1"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000042441"
FT   CHAIN           378..432
FT                   /note="Nucleocapsid protein p7"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000042442"
FT   PEPTIDE         433..440
FT                   /note="Transframe peptide"
FT                   /evidence="ECO:0000255"
FT                   /id="PRO_0000246716"
FT   CHAIN           441..488
FT                   /note="p6-pol"
FT                   /evidence="ECO:0000255"
FT                   /id="PRO_0000042443"
FT   CHAIN           489..587
FT                   /note="Protease"
FT                   /id="PRO_0000038665"
FT   CHAIN           588..1147
FT                   /note="Reverse transcriptase/ribonuclease H"
FT                   /id="PRO_0000042444"
FT   CHAIN           588..1027
FT                   /note="p51 RT"
FT                   /id="PRO_0000042445"
FT   CHAIN           1028..1147
FT                   /note="p15"
FT                   /id="PRO_0000042446"
FT   CHAIN           1148..1435
FT                   /note="Integrase"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000042447"
FT   DOMAIN          508..577
FT                   /note="Peptidase A2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00275"
FT   DOMAIN          631..821
FT                   /note="Reverse transcriptase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00405"
FT   DOMAIN          1021..1144
FT                   /note="RNase H type-1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00408"
FT   DOMAIN          1201..1351
FT                   /note="Integrase catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00457"
FT   ZN_FING         390..407
FT                   /note="CCHC-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00047"
FT   ZN_FING         411..428
FT                   /note="CCHC-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00047"
FT   ZN_FING         1150..1191
FT                   /note="Integrase-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00450"
FT   DNA_BIND        1370..1417
FT                   /note="Integrase-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00506"
FT   REGION          7..31
FT                   /note="Interaction with Gp41"
FT                   /evidence="ECO:0000250|UniProtKB:P12497"
FT   REGION          8..43
FT                   /note="Interaction with host CALM1"
FT                   /evidence="ECO:0000269|PubMed:24500712"
FT   REGION          12..19
FT                   /note="Interaction with host AP3D1"
FT                   /evidence="ECO:0000250|UniProtKB:P12497"
FT   REGION          14..33
FT                   /note="Interaction with membrane phosphatidylinositol 4,5-
FT                   bisphosphate and RNA"
FT                   /evidence="ECO:0000250|UniProtKB:P12497"
FT   REGION          73..77
FT                   /note="Interaction with membrane phosphatidylinositol 4,5-
FT                   bisphosphate"
FT                   /evidence="ECO:0000250|UniProtKB:P12497"
FT   REGION          106..128
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          189..227
FT                   /note="Interaction with host PPIA/CYPA and NUP153"
FT                   /evidence="ECO:0000250|UniProtKB:P12497"
FT   REGION          217..225
FT                   /note="PPIA/CYPA-binding loop"
FT   REGION          277..363
FT                   /note="Dimerization/Multimerization of capsid protein p24"
FT   REGION          448..481
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          489..493
FT                   /note="Dimerization of protease"
FT                   /evidence="ECO:0000269|PubMed:2162350"
FT   REGION          537..543
FT                   /note="Dimerization of protease"
FT                   /evidence="ECO:0000269|PubMed:2162350"
FT   REGION          576..588
FT                   /note="Dimerization of protease"
FT                   /evidence="ECO:0000269|PubMed:2162350"
FT   REGION          814..822
FT                   /note="RT 'primer grip'"
FT                   /evidence="ECO:0000250"
FT   MOTIF           16..22
FT                   /note="Nuclear export signal"
FT                   /evidence="ECO:0000250"
FT   MOTIF           26..32
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000250"
FT   MOTIF           985..1001
FT                   /note="Tryptophan repeat motif"
FT                   /evidence="ECO:0000250"
FT   ACT_SITE        513
FT                   /note="For protease activity; shared with dimeric partner"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10094,
FT                   ECO:0000305|PubMed:33542150"
FT   BINDING         697
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="1"
FT                   /ligand_note="catalytic; for reverse transcriptase
FT                   activity"
FT                   /evidence="ECO:0000250"
FT   BINDING         772
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="1"
FT                   /ligand_note="catalytic; for reverse transcriptase
FT                   activity"
FT                   /evidence="ECO:0000250"
FT   BINDING         773
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="1"
FT                   /ligand_note="catalytic; for reverse transcriptase
FT                   activity"
FT                   /evidence="ECO:0000250"
FT   BINDING         1030
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /ligand_note="catalytic; for RNase H activity"
FT   BINDING         1065
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /ligand_note="catalytic; for RNase H activity"
FT                   /evidence="ECO:0000269|PubMed:12206668"
FT   BINDING         1085
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /ligand_note="catalytic; for RNase H activity"
FT   BINDING         1136
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /ligand_note="catalytic; for RNase H activity"
FT                   /evidence="ECO:0000269|PubMed:12206668"
FT   BINDING         1159
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00450"
FT   BINDING         1163
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00450"
FT   BINDING         1187
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00450"
FT   BINDING         1190
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00450"
FT   BINDING         1211
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="3"
FT                   /ligand_note="catalytic; for integrase activity"
FT                   /evidence="ECO:0000250"
FT   BINDING         1263
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="3"
FT                   /ligand_note="catalytic; for integrase activity"
FT                   /evidence="ECO:0000250"
FT   BINDING         1299
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="3"
FT                   /ligand_note="catalytic; for integrase activity"
FT                   /evidence="ECO:0000305"
FT   SITE            132..133
FT                   /note="Cleavage; by viral protease"
FT                   /evidence="ECO:0000250"
FT   SITE            221..222
FT                   /note="Cis/trans isomerization of proline peptide bond; by
FT                   human PPIA/CYPA"
FT   SITE            363..364
FT                   /note="Cleavage; by viral protease"
FT                   /evidence="ECO:0000250"
FT   SITE            377..378
FT                   /note="Cleavage; by viral protease"
FT                   /evidence="ECO:0000250"
FT   SITE            393..394
FT                   /note="Cleavage; by viral protease"
FT                   /evidence="ECO:0000255"
FT   SITE            426..427
FT                   /note="Cleavage; by viral protease"
FT                   /evidence="ECO:0000255"
FT   SITE            432..433
FT                   /note="Cleavage; by viral protease"
FT                   /evidence="ECO:0000255"
FT   SITE            440..441
FT                   /note="Cleavage; by viral protease"
FT                   /evidence="ECO:0000250"
FT   SITE            488..489
FT                   /note="Cleavage; by viral protease"
FT                   /evidence="ECO:0000305|PubMed:15183348"
FT   SITE            587..588
FT                   /note="Cleavage; by viral protease"
FT                   /evidence="ECO:0000250"
FT   SITE            988
FT                   /note="Essential for RT p66/p51 heterodimerization"
FT                   /evidence="ECO:0000250"
FT   SITE            1001
FT                   /note="Essential for RT p66/p51 heterodimerization"
FT                   /evidence="ECO:0000250"
FT   SITE            1027..1028
FT                   /note="Cleavage; by viral protease; partial"
FT                   /evidence="ECO:0000250"
FT   SITE            1147..1148
FT                   /note="Cleavage; by viral protease"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         132
FT                   /note="Phosphotyrosine; by host"
FT                   /evidence="ECO:0000250"
FT   LIPID           2
FT                   /note="N-myristoyl glycine; by host"
FT                   /evidence="ECO:0000250"
FT   VARIANT         496
FT                   /note="R -> K (confers to resistance to A-77003; when
FT                   associated with other amino acid changes)"
FT   VARIANT         496
FT                   /note="R -> Q (confers to resistance to A-77003)"
FT   VARIANT         498
FT                   /note="L -> F (confers resistance to amprenavir,
FT                   atazanavir, lopinavir; when associated with other amino
FT                   acid changes)"
FT   VARIANT         498
FT                   /note="L -> I (confers resistance to indinavir, lopinavir,
FT                   ritonavir and saquinavir; when associated with other amino
FT                   acid changes)"
FT   VARIANT         498
FT                   /note="L -> R (confers resistance to indinavir and
FT                   lopinavir; when associated with other amino acid changes)"
FT   VARIANT         498
FT                   /note="L -> V (confers resistance to indinavir and
FT                   lopinavir; when associated with other amino acid changes)"
FT   VARIANT         498
FT                   /note="L -> Y (confers resistance to atazanavir; when
FT                   associated with other amino acid changes)"
FT   VARIANT         503
FT                   /note="I -> V (confers resistance to tipranavir)"
FT   VARIANT         504
FT                   /note="G -> E (confers resistance to lopinavir, ritonavir
FT                   and saquinavir; when associated with other amino acid
FT                   changes)"
FT   VARIANT         508
FT                   /note="K -> I (confers resistance to lopinavir)"
FT   VARIANT         508
FT                   /note="K -> M (confers resistance to indinavir, lopinavir
FT                   and nelfinavir; when associated with other amino acid
FT                   changes)"
FT   VARIANT         508
FT                   /note="K -> R (confers resistance to indinavir, lopinavir
FT                   and ritonavir; when associated with other amino acid
FT                   changes)"
FT   VARIANT         511
FT                   /note="L -> I (confers resistance to BILA 2185 BS)"
FT   VARIANT         512
FT                   /note="L -> I (confers resistance to amprenavir, indinavir,
FT                   lopinavir, ritonavir and saquinavir; when associated with
FT                   other amino acid changes)"
FT   VARIANT         518
FT                   /note="D -> N (confers resistance to nelfinavir; when
FT                   associated with other amino acid changes)"
FT   VARIANT         520
FT                   /note="V -> I (confers resistance to A-77003, amprenavir,
FT                   atazanavir, indinavir, kynostatin, lopinavir, ritonavir and
FT                   saquinavir; when associated with other amino acid changes)"
FT   VARIANT         521
FT                   /note="L -> F (confers resistance to atazanavir nelfinavir
FT                   and ritonavir; when associated with other amino acid
FT                   changes)"
FT   VARIANT         522
FT                   /note="E -> Q (confers resistance to lopinavir; when
FT                   associated with other amino acid changes)"
FT   VARIANT         523
FT                   /note="E -> D (confers resistance to tipranavir)"
FT   VARIANT         524
FT                   /note="M -> I (confers resistance to nelfinavir and
FT                   ritonavir; when associated with other amino acid changes)"
FT   VARIANT         524
FT                   /note="M -> L (confers resistance to ritonavir; when
FT                   associated with other amino acid changes)"
FT   VARIANT         525
FT                   /note="S -> D (confers resistance to indinavir and
FT                   tipranavir; when associated with other amino acid changes)"
FT   VARIANT         529
FT                   /note="R -> K (confers resistance to tipranavir)"
FT   VARIANT         533
FT                   /note="K -> I (confers resistance to DMD-323; when
FT                   associated with other amino acid changes)"
FT   VARIANT         534
FT                   /note="M -> F (confers resistance to A-77003)"
FT   VARIANT         534
FT                   /note="M -> I (confers resistance to A-77003, amprenavir,
FT                   atazanavir, indinavir, kynostatin, lopinavir, ritonavir,
FT                   saquinavir and telinavir; when associated with other amino
FT                   acid changes)"
FT   VARIANT         534
FT                   /note="M -> L (confers resistance to A-77003, amprenavir,
FT                   indinavir, lopinavir, ritonavir and saquinavir; when
FT                   associated with other amino acid changes)"
FT   VARIANT         535
FT                   /note="I -> V (confers resistance to amprenavir, lopinavir,
FT                   kynostatin, ritonavir and saquinavir; when associated with
FT                   other amino acid changes)"
FT   VARIANT         536
FT                   /note="G -> V (confers resistance to A-77003, amprenavir,
FT                   indinavir, ritonavir, saquinavir and telinavir; when
FT                   associated with other amino acid changes)"
FT   VARIANT         538
FT                   /note="I -> L (confers resistance to atazanavir; when
FT                   associated with other amino acid changes)"
FT   VARIANT         538
FT                   /note="I -> V (confers resistance to amprenavir, lopinavir
FT                   and ritonavir; when associated with other amino acid
FT                   changes)"
FT   VARIANT         541
FT                   /note="F -> L (confers resistance to lopinavir and
FT                   telinavir; when associated with other amino acid changes)"
FT   VARIANT         541
FT                   /note="F -> Y (confers resistance to indinavir, ritonavir
FT                   and saquinavir; when associated with other amino acid
FT                   changes)"
FT   VARIANT         542
FT                   /note="I -> A (confers resistance to lopinavir)"
FT   VARIANT         542
FT                   /note="I -> L (confers resistance to amprenavir and
FT                   lopinavir; when associated with other amino acid changes)"
FT   VARIANT         542
FT                   /note="I -> M (confers resistance to amprenavir and
FT                   lopinavir)"
FT   VARIANT         542
FT                   /note="I -> S (confers resistance to lopinavir)"
FT   VARIANT         542
FT                   /note="I -> T (confers resistance to lopinavir; when
FT                   associated with other amino acid changes)"
FT   VARIANT         542
FT                   /note="I -> V (confers resistance to indinavir, lopinavir,
FT                   ritonavir and saquinavir; when associated with other amino
FT                   acid changes)"
FT   VARIANT         543
FT                   /note="K -> R (confers resistance to nelfinavir)"
FT   VARIANT         545
FT                   /note="R -> K (confers resistance to nelfinavir)"
FT   VARIANT         546
FT                   /note="Q -> E (confers resistance to lopinavir and
FT                   ritonavir; when associated with other amino acid changes)"
FT   VARIANT         548
FT                   /note="D -> E (confers resistance to tripanavir)"
FT   VARIANT         549
FT                   /note="Q -> H (confers resistance to lopinavir; when
FT                   associated with other amino acid changes)"
FT   VARIANT         551
FT                   /note="L -> P (confers resistance to atazanavir, indinavir,
FT                   lopinavir, ritonavir and saquinavir; when associated with
FT                   other amino acid changes)"
FT   VARIANT         551
FT                   /note="L -> T (confers resistance to lopinavir)"
FT   VARIANT         553
FT                   /note="E -> Q (confers resistance to lopinavir; when
FT                   associated with other amino acid changes)"
FT   VARIANT         554
FT                   /note="I -> F (confers resistance to indinavir, ritonavir
FT                   and saquinavir; when associated with other amino acid
FT                   changes)"
FT   VARIANT         557
FT                   /note="H -> Y (confers resistance to lopinavir; when
FT                   associated with other amino acid changes)"
FT   VARIANT         559
FT                   /note="A -> I (confers resistance to lopinavir; when
FT                   associated with other amino acid changes)"
FT   VARIANT         559
FT                   /note="A -> L (confers resistance to lopinavir; when
FT                   associated with other amino acid changes)"
FT   VARIANT         559
FT                   /note="A -> T (confers resistance to A-77003, indinavir,
FT                   lopinavir, nelfinavir and tripanavir; when associated with
FT                   other amino acid changes)"
FT   VARIANT         559
FT                   /note="A -> V (confers resistance to amprenavir,
FT                   atazanavir, indinavir, kynostatin, lopinavir, nelfinavir,
FT                   ritonavir, saquinavir and telinavir; when associated with
FT                   other amino acid changes)"
FT   VARIANT         561
FT                   /note="G -> S (confers resistance to indinavir, nelfinavir,
FT                   ritonavir and saquinavir; when associated with other amino
FT                   acid changes)"
FT   VARIANT         565
FT                   /note="V -> I (confers resistance to indinavir, nelfinavir,
FT                   ritonavir and saquinavir; when associated with other amino
FT                   acid changes)"
FT   VARIANT         570
FT                   /note="V -> A (confers resistance to A-77003, indinavir,
FT                   lopinavir, nelfinavir, ritonavir and saquinavir; when
FT                   associated with other amino acid changes)"
FT   VARIANT         570
FT                   /note="V -> F (confers resistance to lopinavir and
FT                   ritonavir; when associated with other amino acid changes)"
FT   VARIANT         570
FT                   /note="V -> I (confers resistance to A-77003 and
FT                   kynostatin; when associated with other amino acid changes)"
FT   VARIANT         570
FT                   /note="V -> S (confers resistance to lopinavir and
FT                   ritonavir)"
FT   VARIANT         570
FT                   /note="V -> T (confers resistance to indinavir, lopinavir,
FT                   ritonavir and saquinavir; when associated with other amino
FT                   acid changes)"
FT   VARIANT         572
FT                   /note="I -> A (confers resistance to atazanavir, indinavir,
FT                   lopinavir, nelfinavir, ritonavir and saquinavir; when
FT                   associated with other amino acid changes)"
FT   VARIANT         572
FT                   /note="I -> V (confers resistance to amprenavir,
FT                   atazanavir, indinavir, kynostatin, lopinavir, nelfinavir,
FT                   ritonavir, saquinavir and telinavir; when associated with
FT                   other amino acid changes)"
FT   VARIANT         576
FT                   /note="N -> D (confers resistance to nelfinavir; when
FT                   associated with other amino acid changes)"
FT   VARIANT         576
FT                   /note="N -> S (confers resistance to atazanavir, indinavir
FT                   and nelfinavir; when associated with other amino acid
FT                   changes)"
FT   VARIANT         577
FT                   /note="L -> M (confers resistance to atazanavir; when
FT                   associated with other amino acid changes)"
FT   VARIANT         578
FT                   /note="L -> M (confers resistance to indinavir, lopinavir,
FT                   nelfinavir, ritonavir and saquinavir; when associated with
FT                   other amino acid changes)"
FT   VARIANT         579
FT                   /note="T -> S (confers resistance to lopinavir, ritonavir
FT                   and saquinavir; when associated with other amino acid
FT                   changes)"
FT   VARIANT         581
FT                   /note="I -> L (confers resistance to indinavir)"
FT   VARIANT         628
FT                   /note="M -> L (confers resistance to zidovudine; when
FT                   associated with other amino acid changes)"
FT   VARIANT         631
FT                   /note="E -> A (confers resistance to lamivudine)"
FT   VARIANT         631
FT                   /note="E -> D (confers resistance to zidovudine; when
FT                   associated with other amino acid changes)"
FT   VARIANT         639
FT                   /note="P -> R (confers resistance to stavudine)"
FT   VARIANT         641
FT                   /note="N -> D (confers resistance to stavudine)"
FT   VARIANT         649
FT                   /note="A -> V (confers multi-NRTI resistance; when
FT                   associated with other amino acid changes)"
FT   VARIANT         652
FT                   /note="K -> R (confers resistance to abacavir, adefovir,
FT                   didenosine, lamivudine, stavudine, tenofir and zidovuline;
FT                   when associated with other amino acid changes)"
FT   VARIANT         654
FT                   /note="D -> A (confers resistance to zidovudine)"
FT   VARIANT         654
FT                   /note="D -> E (confers multi-NRTI resistance)"
FT   VARIANT         654
FT                   /note="D -> G (confers multi-NRTI resistance)"
FT   VARIANT         654
FT                   /note="D -> N (confers resistance to zidovudine)"
FT   VARIANT         654
FT                   /note="D -> S (confers multi-NRTI resistance)"
FT   VARIANT         655
FT                   /note="S -> G (confers multi-NRTI resistance; when
FT                   associated with other amino acid changes)"
FT   VARIANT         655
FT                   /note="S -> N (confers multi-NRTI resistance)"
FT   VARIANT         655
FT                   /note="S -> Y (confers multi-NRTI resistance)"
FT   VARIANT         656
FT                   /note="T -> A (confers resistance to lamivudine and
FT                   stavudine)"
FT   VARIANT         656
FT                   /note="T -> D (confers resistance to lamivudine, stavudine
FT                   and rarely to zalcitabine)"
FT   VARIANT         656
FT                   /note="T -> G (confers resistance to didanosine,
FT                   zalcitabine and zidovudine)"
FT   VARIANT         656
FT                   /note="T -> N (confers resistance to lamivudine and
FT                   stavudine)"
FT   VARIANT         657
FT                   /note="K -> E (confers resistance to adefovir and
FT                   lamivudine)"
FT   VARIANT         657
FT                   /note="K -> R (confers resistance to zidovudine; when
FT                   associated with other amino acid changes)"
FT   VARIANT         657
FT                   /note="K -> S (confers resistance to didanosine and
FT                   stavudine)"
FT   VARIANT         661
FT                   /note="L -> I (confers resistance to HBY 097)"
FT   VARIANT         661
FT                   /note="L -> V (confers resistance to abacavir, didanosine,
FT                   HBY 097 and zalcitabine; when associated with other amino
FT                   acid changes)"
FT   VARIANT         662
FT                   /note="V -> I (confers multi-NRTI resistance; when
FT                   associated with other amino acid changes)"
FT   VARIANT         662
FT                   /note="V -> L (confers resistance to HBY 097)"
FT   VARIANT         662
FT                   /note="V -> M (confers resistance to stavudine and
FT                   zalcitabine)"
FT   VARIANT         662
FT                   /note="V -> T (confers resistance to d4C, didanosine,
FT                   stavudine and zalcitabine)"
FT   VARIANT         664
FT                   /note="F -> L (confers multi-NRTI resistance; when
FT                   associated with other amino acid changes)"
FT   VARIANT         675
FT                   /note="W -> G (confers resistance to pyrophosphate analog
FT                   PFA)"
FT   VARIANT         675
FT                   /note="W -> S (confers resistance to pyrophosphate analog
FT                   PFA)"
FT   VARIANT         676
FT                   /note="E -> G (confers resistance to pyrophosphate analog
FT                   PFA)"
FT   VARIANT         676
FT                   /note="E -> K (confers resistance to pyrophosphate analog
FT                   PFA)"
FT   VARIANT         679
FT                   /note="L -> I (confers resistance to pyrophosphate analog
FT                   PFA)"
FT   VARIANT         687
FT                   /note="L -> I (confers resistance to nevirapine and
FT                   efavirenz)"
FT   VARIANT         688
FT                   /note="K -> E (confers resistance to atevirdine, efavirenz,
FT                   nevirapine and zidovudine)"
FT   VARIANT         688
FT                   /note="K -> P (confers resistance to TMC125; when
FT                   associated with E-142)"
FT   VARIANT         688
FT                   /note="K -> Q (confers resistance to efavirenz; when
FT                   associated with I-19)"
FT   VARIANT         690
FT                   /note="K -> E (confers resistance to atevirdine; when
FT                   associated with other amino acid changes)"
FT   VARIANT         690
FT                   /note="K -> N (confers resistance to atevirdine, efavirenz,
FT                   emivirine and nevirapine; when associated with other amino
FT                   acid changes)"
FT   VARIANT         690
FT                   /note="K -> R (confers resistance to emivirine and
FT                   trovirdine; when associated with other D-179 and C-181)"
FT   VARIANT         693
FT                   /note="V -> A (confers resistance to nevirapine)"
FT   VARIANT         693
FT                   /note="V -> I (confers resistance to HBY 097)"
FT   VARIANT         693
FT                   /note="V -> M (confers resistance to delavirdine, efavirenz
FT                   and nevirapine)"
FT   VARIANT         695
FT                   /note="V -> I (confers resistance to efavirenz, emivirine,
FT                   nevirapine and trovirdine; when associated with other amino
FT                   acid changes)"
FT   VARIANT         702
FT                   /note="Y -> F (confers resistance to abacavir; when
FT                   associated with other amino acid changes)"
FT   VARIANT         703
FT                   /note="F -> Y (confers multi-NRTI resistance; when
FT                   associated with other amino acid changes)"
FT   VARIANT         705
FT                   /note="V -> I (confers resistance to zidovudine; when
FT                   associated with other amino acid changes)"
FT   VARIANT         706
FT                   /note="P -> S (confers resistance to lodenosine)"
FT   VARIANT         722
FT                   /note="I -> L (confers resistance to delavirdine, efavirenz
FT                   and nevirapine; when associated with I-239)"
FT   VARIANT         722
FT                   /note="I -> M (confers resistance to delavirdine, efavirenz
FT                   and nevirapine; when associated with I-239)"
FT   VARIANT         722
FT                   /note="I -> T (confers resistance to delavirdine, efavirenz
FT                   and nevirapine; when associated with I-239)"
FT   VARIANT         725
FT                   /note="E -> K (confers resistance to emivirine)"
FT   VARIANT         732
FT                   /note="Q -> M (confers both multi-NRTI and multi-NNRTI
FT                   resistance)"
FT   VARIANT         738
FT                   /note="Q -> M (confers multi-NRTI resistance; when
FT                   associated with other amino acid changes)"
FT   VARIANT         743
FT                   /note="S -> A (confers resistance to pyrophosphate analog
FT                   PFA)"
FT   VARIANT         744
FT                   /note="P -> S (confers resistance to lamivudine)"
FT   VARIANT         748
FT                   /note="Q -> L (confers resistance to pyrophosphate analog
FT                   PFA)"
FT   VARIANT         766
FT                   /note="V -> D (confers resistance to efavirenz, tivirapine
FT                   and trovirdine; when associated with other amino acid
FT                   changes)"
FT   VARIANT         768
FT                   /note="Y -> C (confers multi-NNRTI resistance)"
FT   VARIANT         771
FT                   /note="M -> I (confers resistance to lamivudine and
FT                   emtricitabine)"
FT   VARIANT         771
FT                   /note="M -> T (confers resistance to abacavir, didanosine,
FT                   emtricitabine, lamivudine and zalcitabine)"
FT   VARIANT         771
FT                   /note="M -> V (confers resistance to lamivudine)"
FT   VARIANT         775
FT                   /note="Y -> C (confers resistance to nevirapine)"
FT   VARIANT         775
FT                   /note="Y -> H (confers resistance to atevirdine, efavirenz,
FT                   loviride and zidovudine)"
FT   VARIANT         775
FT                   /note="Y -> L (confers resistance to efavirenz)"
FT   VARIANT         776
FT                   /note="V -> I (confers resistance to HBY 097)"
FT   VARIANT         777
FT                   /note="G -> A (confers resistance to efavirenz and
FT                   nevirapine)"
FT   VARIANT         777
FT                   /note="G -> C (confers resistance to efavirenz and
FT                   nevirapine)"
FT   VARIANT         777
FT                   /note="G -> E (confers resistance to efavirenz, nevirapine
FT                   and quinoxaline)"
FT   VARIANT         777
FT                   /note="G -> Q (confers resistance to efavirenz, HBY 097 and
FT                   nevirapine)"
FT   VARIANT         777
FT                   /note="G -> S (confers resistance to efavirenz and
FT                   nevirapine)"
FT   VARIANT         777
FT                   /note="G -> T (confers resistance to efavirenz, HBY 097 and
FT                   nevirapine)"
FT   VARIANT         777
FT                   /note="G -> V (confers resistance to efavirenz and
FT                   nevirapine)"
FT   VARIANT         795
FT                   /note="H -> Y (confers resistance to lamivudine,
FT                   pyrophosphate analog PFA and zidovudine)"
FT   VARIANT         797
FT                   /note="L -> W (confers resistance to zidovudine)"
FT   VARIANT         798
FT                   /note="R -> K (confers resistance to lamivudine and
FT                   zidovudine)"
FT   VARIANT         801
FT                   /note="L -> F (confers resistance to ph-AZT and
FT                   zidovudine)"
FT   VARIANT         802
FT                   /note="T -> F (confers resistance to zidovudine; when
FT                   associated with other amino acid changes)"
FT   VARIANT         802
FT                   /note="T -> Y (confers resistance to zidovudine; when
FT                   associated with other amino acid changes)"
FT   VARIANT         806
FT                   /note="K -> E (confers resistance to zidovudine)"
FT   VARIANT         806
FT                   /note="K -> Q (confers resistance to zidovudine; when
FT                   associated with other amino acid changes)"
FT   VARIANT         806
FT                   /note="K -> R (confers resistance to lamivudine, stavudine,
FT                   zalcicabine and zidovudine)"
FT   VARIANT         812
FT                   /note="P -> H (confers resistance to efavirenz, emivirine,
FT                   HBY 097 and quinoxaline; when associated with A-17)"
FT   VARIANT         823
FT                   /note="P -> L (confers resistance to atevirdine and
FT                   delavirdine)"
FT   VARIANT         825
FT                   /note="K -> T (confers resistance to atevirdine and
FT                   zidovudine; when associated with other amino acid changes)"
FT   VARIANT         870
FT                   /note="L -> I (confers resistance to delavirdine, efavirenz
FT                   and nevirapine)"
FT   VARIANT         905
FT                   /note="Y -> F (confers resistance to delavirdine and
FT                   nevirapine)"
FT   VARIANT         920
FT                   /note="G -> D (confers resistance to abacavir, lamivudine
FT                   and zidovudine)"
FT   VARIANT         920
FT                   /note="G -> E (confers resistance to abacavir, lamivudine
FT                   and zidovudine)"
FT   VARIANT         973
FT                   /note="T -> I (confers resistance to abacavir, lamivudine
FT                   and zidovudine)"
FT   MUTAGEN         6
FT                   /note="S->D: No influence on the PIP2- or
FT                   concentration-dependent myristyl switch mechanism."
FT                   /evidence="ECO:0000269|PubMed:17656588"
FT   MUTAGEN         9
FT                   /note="S->D: No influence on the PIP2- or
FT                   concentration-dependent myristyl switch mechanism."
FT                   /evidence="ECO:0000269|PubMed:17656588"
FT   MUTAGEN         18
FT                   /note="K->A: Replication-defective, induces nuclear
FT                   mislocalization of matrix protein; when associated with
FT                   G-22."
FT                   /evidence="ECO:0000269|PubMed:10604476"
FT   MUTAGEN         22
FT                   /note="R->G: Replication-defective, induces nuclear
FT                   mislocalization of matrix protein; when associated with
FT                   A-18."
FT                   /evidence="ECO:0000269|PubMed:10604476"
FT   MUTAGEN         27
FT                   /note="K->A: No effect on subcellular localization of
FT                   matrix protein; when associated with A-18 and G-22."
FT                   /evidence="ECO:0000269|PubMed:10604476"
FT   MUTAGEN         67
FT                   /note="S->D: No influence on the PIP2- or
FT                   concentration-dependent myristyl switch mechanism."
FT                   /evidence="ECO:0000269|PubMed:17656588"
FT   MUTAGEN         72
FT                   /note="S->D: No influence on the PIP2- or
FT                   concentration-dependent myristyl switch mechanism."
FT                   /evidence="ECO:0000269|PubMed:17656588"
FT   MUTAGEN         217
FT                   /note="P->A: 3-fold decrease of PPIA-binding affinity."
FT                   /evidence="ECO:0000269|PubMed:9223641"
FT   MUTAGEN         218
FT                   /note="V->A: 2.7-fold decrease of PPIA-binding affinity."
FT                   /evidence="ECO:0000269|PubMed:9223641"
FT   MUTAGEN         219
FT                   /note="H->A,Q: 8-fold decrease of PPIA-binding affinity."
FT                   /evidence="ECO:0000269|PubMed:9223641"
FT   MUTAGEN         220
FT                   /note="A->G: 44-fold decrease of PPIA-binding affinity."
FT                   /evidence="ECO:0000269|PubMed:9223641"
FT   MUTAGEN         220
FT                   /note="A->V: 3.4-fold decrease of PPIA-binding affinity."
FT                   /evidence="ECO:0000269|PubMed:9223641"
FT   MUTAGEN         221
FT                   /note="G->A: 31-fold decrease of PPIA-binding affinity."
FT                   /evidence="ECO:0000269|PubMed:9223641"
FT   MUTAGEN         221
FT                   /note="G->V: 154-fold decrease of PPIA-binding affinity."
FT                   /evidence="ECO:0000269|PubMed:9223641"
FT   MUTAGEN         222
FT                   /note="P->A: 36-fold decrease of PPIA-binding affinity."
FT                   /evidence="ECO:0000269|PubMed:9223641"
FT   MUTAGEN         222
FT                   /note="P->V: More than 150-fold decrease of PPIA-binding
FT                   affinity."
FT                   /evidence="ECO:0000269|PubMed:9223641"
FT   MUTAGEN         223
FT                   /note="I->A: 1.2-fold decrease of PPIA-binding affinity."
FT                   /evidence="ECO:0000269|PubMed:9223641"
FT   MUTAGEN         223
FT                   /note="I->V: 1.0-fold decrease of PPIA-binding affinity."
FT                   /evidence="ECO:0000269|PubMed:9223641"
FT   MUTAGEN         224
FT                   /note="A->G: 2.3-fold decrease of PPIA-binding affinity."
FT                   /evidence="ECO:0000269|PubMed:9223641"
FT   MUTAGEN         224
FT                   /note="A->V: 1.7-fold decrease of PPIA-binding affinity."
FT                   /evidence="ECO:0000269|PubMed:9223641"
FT   MUTAGEN         225
FT                   /note="P->A: 1.6-fold decrease of PPIA-binding affinity."
FT                   /evidence="ECO:0000269|PubMed:9223641"
FT   MUTAGEN         394
FT                   /note="N->F,G: Decreases infectivity and replication."
FT                   /evidence="ECO:0000269|PubMed:16904152"
FT   MUTAGEN         400
FT                   /note="H->C: Complete loss of infectivity and in vitro
FT                   chaperone activity."
FT                   /evidence="ECO:0000269|PubMed:11932404"
FT   MUTAGEN         405
FT                   /note="C->H: Complete loss of infectivity and DNA
FT                   synthesis."
FT                   /evidence="ECO:0000269|PubMed:11932404"
FT   MUTAGEN         421
FT                   /note="H->C: Partial loss of infectivity. Complete loss of
FT                   in vitro chaperone activity."
FT                   /evidence="ECO:0000269|PubMed:11932404"
FT   MUTAGEN         426
FT                   /note="C->H: Partial loss of infectivity."
FT                   /evidence="ECO:0000269|PubMed:11932404"
FT   MUTAGEN         488..490
FT                   /note="FPQ->IPK: Complete loss of RT p66/p51 cleavage."
FT                   /evidence="ECO:0000269|PubMed:15183348"
FT   MUTAGEN         513
FT                   /note="D->H: Abolished protease activity."
FT                   /evidence="ECO:0000269|PubMed:33542150"
FT   MUTAGEN         821
FT                   /note="L->A: Complete loss of RT dimerization."
FT                   /evidence="ECO:0000269|PubMed:15183348"
FT   MUTAGEN         1065
FT                   /note="E->Q: Complete loss of RNase H activity."
FT                   /evidence="ECO:0000269|PubMed:12206668"
FT   MUTAGEN         1136
FT                   /note="D->N: Complete loss of RNase H activity."
FT                   /evidence="ECO:0000269|PubMed:12206668"
FT   MUTAGEN         1159
FT                   /note="H->C: No effect on integrase activity in vitro."
FT                   /evidence="ECO:0000269|PubMed:8420982"
FT   MUTAGEN         1163
FT                   /note="H->C,V: 75% increase of integrase activity in
FT                   vitro."
FT                   /evidence="ECO:0000269|PubMed:8420982"
FT   MUTAGEN         1187
FT                   /note="C->A: Complete loss of integrase activity in vivo."
FT                   /evidence="ECO:0000269|PubMed:8035478"
FT   MUTAGEN         1190
FT                   /note="C->A: Complete loss of integrase activity in vivo."
FT                   /evidence="ECO:0000269|PubMed:8035478"
FT   MUTAGEN         1200
FT                   /note="Q->C: 75% increase of integrase activity in vitro."
FT                   /evidence="ECO:0000269|PubMed:8420982"
FT   MUTAGEN         1208
FT                   /note="W->A: Complete loss of integrase activity in vivo."
FT                   /evidence="ECO:0000269|PubMed:8035478"
FT   MUTAGEN         1211
FT                   /note="D->A,V: Complete loss of integrase activity in vivo
FT                   and in vitro."
FT                   /evidence="ECO:0000269|PubMed:8035478,
FT                   ECO:0000269|PubMed:8420982, ECO:0000269|PubMed:9573231"
FT   MUTAGEN         1213
FT                   /note="T->A: No effect on infectivity."
FT                   /evidence="ECO:0000269|PubMed:8035478"
FT   MUTAGEN         1222
FT                   /note="V->P: Complete loss of integrase activity."
FT                   /evidence="ECO:0000269|PubMed:8035478"
FT   MUTAGEN         1228
FT                   /note="S->A: Complete loss of integrase activity in vivo."
FT                   /evidence="ECO:0000269|PubMed:8035478,
FT                   ECO:0000269|PubMed:8420982"
FT   MUTAGEN         1228
FT                   /note="S->R: No effect on integrase activity in vitro."
FT                   /evidence="ECO:0000269|PubMed:8035478,
FT                   ECO:0000269|PubMed:8420982"
FT   MUTAGEN         1262
FT                   /note="T->A: No effect infectivity."
FT                   /evidence="ECO:0000269|PubMed:8035478"
FT   MUTAGEN         1263
FT                   /note="D->A,I: Complete loss of integrase activity in vivo
FT                   and in vitro."
FT                   /evidence="ECO:0000269|PubMed:8035478,
FT                   ECO:0000269|PubMed:8420982, ECO:0000269|PubMed:9573231"
FT   MUTAGEN         1270
FT                   /note="G->A: No effect on infectivity."
FT                   /evidence="ECO:0000269|PubMed:8035478"
FT   MUTAGEN         1282
FT                   /note="I->P: Complete loss of integrase activity in vivo."
FT                   /evidence="ECO:0000269|PubMed:8035478"
FT   MUTAGEN         1298
FT                   /note="V->A: No effect on infectivity."
FT                   /evidence="ECO:0000269|PubMed:8035478"
FT   MUTAGEN         1299
FT                   /note="E->G,P: Complete loss of integrase activity in
FT                   vitro."
FT                   /evidence="ECO:0000269|PubMed:8035478,
FT                   ECO:0000269|PubMed:8420982, ECO:0000269|PubMed:9573231"
FT   MUTAGEN         1306
FT                   /note="K->P: Slow down virus replication."
FT                   /evidence="ECO:0000269|PubMed:8035478"
FT   MUTAGEN         1326
FT                   /note="A->P: Complete loss of integrase activity in vivo."
FT                   /evidence="ECO:0000269|PubMed:8035478"
FT   MUTAGEN         1346
FT                   /note="R->C: 75% increase of integrase activity in vitro."
FT                   /evidence="ECO:0000269|PubMed:8420982"
FT   MUTAGEN         1382
FT                   /note="W->A: Complete loss of infectivity. No effect on
FT                   integrase activity in vitro."
FT                   /evidence="ECO:0000269|PubMed:8035478,
FT                   ECO:0000269|PubMed:8420982"
FT   MUTAGEN         1382
FT                   /note="W->E: 75% increase of integrase activity in vitro."
FT                   /evidence="ECO:0000269|PubMed:8035478,
FT                   ECO:0000269|PubMed:8420982"
FT   STRAND          7..10
FT                   /evidence="ECO:0007829|PDB:1TAM"
FT   HELIX           11..18
FT                   /evidence="ECO:0007829|PDB:1TAM"
FT   STRAND          19..21
FT                   /evidence="ECO:0007829|PDB:1TAM"
FT   STRAND          23..25
FT                   /evidence="ECO:0007829|PDB:1TAM"
FT   HELIX           31..45
FT                   /evidence="ECO:0007829|PDB:1TAM"
FT   STRAND          46..48
FT                   /evidence="ECO:0007829|PDB:1TAM"
FT   TURN            50..52
FT                   /evidence="ECO:0007829|PDB:1TAM"
FT   HELIX           54..67
FT                   /evidence="ECO:0007829|PDB:1TAM"
FT   TURN            68..70
FT                   /evidence="ECO:0007829|PDB:1TAM"
FT   HELIX           72..90
FT                   /evidence="ECO:0007829|PDB:1TAM"
FT   HELIX           97..108
FT                   /evidence="ECO:0007829|PDB:1TAM"
FT   HELIX           109..112
FT                   /evidence="ECO:0007829|PDB:1TAM"
FT   STRAND          116..118
FT                   /evidence="ECO:0007829|PDB:1TAM"
FT   HELIX           149..162
FT                   /evidence="ECO:0007829|PDB:1E6J"
FT   HELIX           168..175
FT                   /evidence="ECO:0007829|PDB:1E6J"
FT   TURN            176..178
FT                   /evidence="ECO:0007829|PDB:1E6J"
FT   HELIX           181..189
FT                   /evidence="ECO:0007829|PDB:1E6J"
FT   HELIX           195..215
FT                   /evidence="ECO:0007829|PDB:1E6J"
FT   HELIX           233..236
FT                   /evidence="ECO:0007829|PDB:1E6J"
FT   TURN            237..240
FT                   /evidence="ECO:0007829|PDB:1E6J"
FT   HELIX           243..250
FT                   /evidence="ECO:0007829|PDB:1E6J"
FT   STRAND          251..254
FT                   /evidence="ECO:0007829|PDB:1E6J"
FT   TURN            268..271
FT                   /evidence="ECO:0007829|PDB:6VPZ"
FT   HELIX           282..284
FT                   /evidence="ECO:0007829|PDB:1E6J"
FT   HELIX           293..305
FT                   /evidence="ECO:0007829|PDB:1E6J"
FT   HELIX           311..324
FT                   /evidence="ECO:0007829|PDB:1E6J"
FT   HELIX           328..337
FT                   /evidence="ECO:0007829|PDB:1E6J"
FT   HELIX           343..349
FT                   /evidence="ECO:0007829|PDB:1E6J"
FT   TURN            350..353
FT                   /evidence="ECO:0007829|PDB:2KOD"
FT   STRAND          357..360
FT                   /evidence="ECO:0007829|PDB:2KOD"
FT   STRAND          393..395
FT                   /evidence="ECO:0007829|PDB:1ESK"
FT   TURN            402..404
FT                   /evidence="ECO:0007829|PDB:1ESK"
FT   STRAND          414..416
FT                   /evidence="ECO:0007829|PDB:1ESK"
FT   TURN            423..425
FT                   /evidence="ECO:0007829|PDB:1ESK"
FT   STRAND          490..492
FT                   /evidence="ECO:0007829|PDB:1HVR"
FT   STRAND          493..495
FT                   /evidence="ECO:0007829|PDB:6DV4"
FT   STRAND          498..503
FT                   /evidence="ECO:0007829|PDB:6DV4"
FT   STRAND          506..512
FT                   /evidence="ECO:0007829|PDB:6DV4"
FT   STRAND          517..521
FT                   /evidence="ECO:0007829|PDB:6DV4"
FT   STRAND          530..537
FT                   /evidence="ECO:0007829|PDB:6DV4"
FT   STRAND          540..554
FT                   /evidence="ECO:0007829|PDB:6DV4"
FT   STRAND          557..566
FT                   /evidence="ECO:0007829|PDB:6DV4"
FT   STRAND          569..573
FT                   /evidence="ECO:0007829|PDB:1ODW"
FT   HELIX           575..578
FT                   /evidence="ECO:0007829|PDB:6DV4"
FT   TURN            579..582
FT                   /evidence="ECO:0007829|PDB:6DV4"
FT   STRAND          584..586
FT                   /evidence="ECO:0007829|PDB:6DV4"
FT   HELIX           591..593
FT                   /evidence="ECO:0007829|PDB:8TCM"
FT   STRAND          597..599
FT                   /evidence="ECO:0007829|PDB:7DPQ"
FT   STRAND          600..602
FT                   /evidence="ECO:0007829|PDB:2RF2"
FT   STRAND          607..611
FT                   /evidence="ECO:0007829|PDB:2WHH"
FT   STRAND          613..618
FT                   /evidence="ECO:0007829|PDB:3KT2"
FT   HELIX           625..629
FT                   /evidence="ECO:0007829|PDB:3KJV"
FT   TURN            630..632
FT                   /evidence="ECO:0007829|PDB:1VRU"
FT   STRAND          633..636
FT                   /evidence="ECO:0007829|PDB:8TCM"
FT   STRAND          639..641
FT                   /evidence="ECO:0007829|PDB:2RF2"
FT   STRAND          647..650
FT                   /evidence="ECO:0007829|PDB:8TCM"
FT   TURN            653..656
FT                   /evidence="ECO:0007829|PDB:3LAK"
FT   STRAND          659..662
FT                   /evidence="ECO:0007829|PDB:8TCM"
FT   HELIX           665..670
FT                   /evidence="ECO:0007829|PDB:8TCM"
FT   HELIX           672..676
FT                   /evidence="ECO:0007829|PDB:3QIP"
FT   TURN            677..679
FT                   /evidence="ECO:0007829|PDB:3QIP"
FT   HELIX           684..686
FT                   /evidence="ECO:0007829|PDB:7SLS"
FT   HELIX           687..689
FT                   /evidence="ECO:0007829|PDB:8TCM"
FT   STRAND          690..697
FT                   /evidence="ECO:0007829|PDB:8TCM"
FT   HELIX           699..704
FT                   /evidence="ECO:0007829|PDB:8TCM"
FT   STRAND          705..707
FT                   /evidence="ECO:0007829|PDB:1EP4"
FT   TURN            709..711
FT                   /evidence="ECO:0007829|PDB:8TCM"
FT   HELIX           712..715
FT                   /evidence="ECO:0007829|PDB:8TCM"
FT   STRAND          717..719
FT                   /evidence="ECO:0007829|PDB:8TCM"
FT   HELIX           722..724
FT                   /evidence="ECO:0007829|PDB:8TCM"
FT   STRAND          725..727
FT                   /evidence="ECO:0007829|PDB:8TCK"
FT   STRAND          729..735
FT                   /evidence="ECO:0007829|PDB:8TCM"
FT   HELIX           742..761
FT                   /evidence="ECO:0007829|PDB:8TCM"
FT   STRAND          762..765
FT                   /evidence="ECO:0007829|PDB:1C0T"
FT   STRAND          766..770
FT                   /evidence="ECO:0007829|PDB:8TCM"
FT   STRAND          773..778
FT                   /evidence="ECO:0007829|PDB:8TCM"
FT   HELIX           782..798
FT                   /evidence="ECO:0007829|PDB:8TCM"
FT   TURN            806..808
FT                   /evidence="ECO:0007829|PDB:7SLS"
FT   TURN            813..816
FT                   /evidence="ECO:0007829|PDB:8TCJ"
FT   STRAND          819..821
FT                   /evidence="ECO:0007829|PDB:8TCM"
FT   HELIX           823..825
FT                   /evidence="ECO:0007829|PDB:8TCM"
FT   STRAND          826..828
FT                   /evidence="ECO:0007829|PDB:7SLS"
FT   STRAND          837..840
FT                   /evidence="ECO:0007829|PDB:1RTH"
FT   HELIX           841..854
FT                   /evidence="ECO:0007829|PDB:7SLS"
FT   TURN            855..857
FT                   /evidence="ECO:0007829|PDB:7SLS"
FT   STRAND          858..860
FT                   /evidence="ECO:0007829|PDB:3DOL"
FT   HELIX           864..869
FT                   /evidence="ECO:0007829|PDB:7SLS"
FT   TURN            870..872
FT                   /evidence="ECO:0007829|PDB:3QIP"
FT   STRAND          876..879
FT                   /evidence="ECO:0007829|PDB:2YNI"
FT   HELIX           884..897
FT                   /evidence="ECO:0007829|PDB:7SLS"
FT   STRAND          902..904
FT                   /evidence="ECO:0007829|PDB:1JLG"
FT   STRAND          908..910
FT                   /evidence="ECO:0007829|PDB:6P1X"
FT   STRAND          913..919
FT                   /evidence="ECO:0007829|PDB:8TCM"
FT   TURN            920..922
FT                   /evidence="ECO:0007829|PDB:8TCM"
FT   STRAND          923..929
FT                   /evidence="ECO:0007829|PDB:8TCM"
FT   STRAND          937..942
FT                   /evidence="ECO:0007829|PDB:8TCM"
FT   STRAND          945..949
FT                   /evidence="ECO:0007829|PDB:3QIP"
FT   HELIX           951..970
FT                   /evidence="ECO:0007829|PDB:8TCM"
FT   STRAND          975..977
FT                   /evidence="ECO:0007829|PDB:8TCM"
FT   HELIX           982..992
FT                   /evidence="ECO:0007829|PDB:8TCM"
FT   STRAND          993..995
FT                   /evidence="ECO:0007829|PDB:7SLS"
FT   STRAND          1001..1003
FT                   /evidence="ECO:0007829|PDB:8TCJ"
FT   HELIX           1008..1013
FT                   /evidence="ECO:0007829|PDB:3QIP"
FT   STRAND          1022..1024
FT                   /evidence="ECO:0007829|PDB:1RT2"
FT   STRAND          1025..1033
FT                   /evidence="ECO:0007829|PDB:3QIO"
FT   TURN            1035..1037
FT                   /evidence="ECO:0007829|PDB:3QIO"
FT   STRAND          1040..1046
FT                   /evidence="ECO:0007829|PDB:3QIO"
FT   STRAND          1047..1049
FT                   /evidence="ECO:0007829|PDB:3DRP"
FT   STRAND          1051..1058
FT                   /evidence="ECO:0007829|PDB:3QIO"
FT   HELIX           1061..1075
FT                   /evidence="ECO:0007829|PDB:3QIO"
FT   STRAND          1078..1085
FT                   /evidence="ECO:0007829|PDB:3QIO"
FT   HELIX           1087..1093
FT                   /evidence="ECO:0007829|PDB:3QIO"
FT   STRAND          1098..1102
FT                   /evidence="ECO:0007829|PDB:3QIP"
FT   HELIX           1105..1112
FT                   /evidence="ECO:0007829|PDB:3QIO"
FT   STRAND          1116..1122
FT                   /evidence="ECO:0007829|PDB:3QIO"
FT   STRAND          1125..1127
FT                   /evidence="ECO:0007829|PDB:3LP1"
FT   HELIX           1130..1140
FT                   /evidence="ECO:0007829|PDB:3QIO"
FT   TURN            1141..1143
FT                   /evidence="ECO:0007829|PDB:3QIO"
FT   HELIX           1204..1206
FT                   /evidence="ECO:0007829|PDB:1EXQ"
FT   STRAND          1207..1215
FT                   /evidence="ECO:0007829|PDB:1EXQ"
FT   STRAND          1218..1225
FT                   /evidence="ECO:0007829|PDB:1EXQ"
FT   TURN            1226..1228
FT                   /evidence="ECO:0007829|PDB:1EXQ"
FT   STRAND          1231..1240
FT                   /evidence="ECO:0007829|PDB:1EXQ"
FT   HELIX           1241..1254
FT                   /evidence="ECO:0007829|PDB:1EXQ"
FT   STRAND          1259..1261
FT                   /evidence="ECO:0007829|PDB:1EXQ"
FT   HELIX           1266..1268
FT                   /evidence="ECO:0007829|PDB:1EXQ"
FT   HELIX           1271..1280
FT                   /evidence="ECO:0007829|PDB:1EXQ"
FT   STRAND          1283..1285
FT                   /evidence="ECO:0007829|PDB:6EX9"
FT   HELIX           1292..1294
FT                   /evidence="ECO:0007829|PDB:5HRN"
FT   HELIX           1302..1312
FT                   /evidence="ECO:0007829|PDB:1EXQ"
FT   HELIX           1313..1315
FT                   /evidence="ECO:0007829|PDB:1EXQ"
FT   HELIX           1319..1332
FT                   /evidence="ECO:0007829|PDB:1EXQ"
FT   STRAND          1335..1339
FT                   /evidence="ECO:0007829|PDB:1EXQ"
FT   HELIX           1343..1355
FT                   /evidence="ECO:0007829|PDB:1EXQ"
FT   HELIX           1358..1368
FT                   /evidence="ECO:0007829|PDB:1EX4"
FT   STRAND          1371..1375
FT                   /evidence="ECO:0007829|PDB:5TC2"
FT   STRAND          1377..1380
FT                   /evidence="ECO:0007829|PDB:5TC2"
FT   STRAND          1382..1392
FT                   /evidence="ECO:0007829|PDB:5TC2"
FT   STRAND          1395..1400
FT                   /evidence="ECO:0007829|PDB:5TC2"
FT   STRAND          1403..1408
FT                   /evidence="ECO:0007829|PDB:5TC2"
FT   HELIX           1409..1411
FT                   /evidence="ECO:0007829|PDB:5TC2"
FT   STRAND          1412..1415
FT                   /evidence="ECO:0007829|PDB:5TC2"
SQ   SEQUENCE   1435 AA;  162042 MW;  8487B36BDEAC5FE4 CRC64;
     MGARASVLSG GELDRWEKIR LRPGGKKKYK LKHIVWASRE LERFAVNPGL LETSEGCRQI
     LGQLQPSLQT GSEELRSLYN TVATLYCVHQ RIEIKDTKEA LDKIEEEQNK SKKKAQQAAA
     DTGHSNQVSQ NYPIVQNIQG QMVHQAISPR TLNAWVKVVE EKAFSPEVIP MFSALSEGAT
     PQDLNTMLNT VGGHQAAMQM LKETINEEAA EWDRVHPVHA GPIAPGQMRE PRGSDIAGTT
     STLQEQIGWM TNNPPIPVGE IYKRWIILGL NKIVRMYSPT SILDIRQGPK EPFRDYVDRF
     YKTLRAEQAS QEVKNWMTET LLVQNANPDC KTILKALGPA ATLEEMMTAC QGVGGPGHKA
     RVLAEAMSQV TNSATIMMQR GNFRNQRKIV KCFNCGKEGH TARNCRAPRK KGCWKCGKEG
     HQMKDCTERQ ANFLREDLAF LQGKAREFSS EQTRANSPTR RELQVWGRDN NSPSEAGADR
     QGTVSFNFPQ VTLWQRPLVT IKIGGQLKEA LLDTGADDTV LEEMSLPGRW KPKMIGGIGG
     FIKVRQYDQI LIEICGHKAI GTVLVGPTPV NIIGRNLLTQ IGCTLNFPIS PIETVPVKLK
     PGMDGPKVKQ WPLTEEKIKA LVEICTEMEK EGKISKIGPE NPYNTPVFAI KKKDSTKWRK
     LVDFRELNKR TQDFWEVQLG IPHPAGLKKK KSVTVLDVGD AYFSVPLDED FRKYTAFTIP
     SINNETPGIR YQYNVLPQGW KGSPAIFQSS MTKILEPFRK QNPDIVIYQY MDDLYVGSDL
     EIGQHRTKIE ELRQHLLRWG LTTPDKKHQK EPPFLWMGYE LHPDKWTVQP IVLPEKDSWT
     VNDIQKLVGK LNWASQIYPG IKVRQLCKLL RGTKALTEVI PLTEEAELEL AENREILKEP
     VHGVYYDPSK DLIAEIQKQG QGQWTYQIYQ EPFKNLKTGK YARMRGAHTN DVKQLTEAVQ
     KITTESIVIW GKTPKFKLPI QKETWETWWT EYWQATWIPE WEFVNTPPLV KLWYQLEKEP
     IVGAETFYVD GAANRETKLG KAGYVTNRGR QKVVTLTDTT NQKTELQAIY LALQDSGLEV
     NIVTDSQYAL GIIQAQPDQS ESELVNQIIE QLIKKEKVYL AWVPAHKGIG GNEQVDKLVS
     AGIRKVLFLD GIDKAQDEHE KYHSNWRAMA SDFNLPPVVA KEIVASCDKC QLKGEAMHGQ
     VDCSPGIWQL DCTHLEGKVI LVAVHVASGY IEAEVIPAET GQETAYFLLK LAGRWPVKTI
     HTDNGSNFTG ATVRAACWWA GIKQEFGIPY NPQSQGVVES MNKELKKIIG QVRDQAEHLK
     TAVQMAVFIH NFKRKGGIGG YSAGERIVDI IATDIQTKEL QKQITKIQNF RVYYRDSRNP
     LWKGPAKLLW KGEGAVVIQD NSDIKVVPRR KAKIIRDYGK QMAGDDCVAS RQDED
//
